0001437749-22-004662 | 10-K | XBRL Viewer

Print Document View Excel Document

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating activities
Net income	$ 26,907	$ 21,220	$ 17,934
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	11,070	8,395	5,416
Stock-based compensation	3,479	3,022	2,642
Fair value adjustments to contingent consideration obligations	(674)	182	171
Provision for doubtful accounts and allowances	263	293	388
Provision for inventory write-downs	3,779	1,523	747
Provision (benefit) for deferred income taxes	79	(328)	824
Gains on sale of building, acquisitions and divestitures	0	(470)	0
Foreign currency transaction gain	163	100	(57)
Changes in operating assets and liabilities:
Accounts receivable	(818)	(939)	(1,301)
Inventory and other deferred costs	(5,485)	(2,609)	(11,335)
Prepaid expenses and other assets	(1,927)	89	(654)
Accounts payable and other liabilities	(1,734)	4,322	(596)
Net cash provided by operating activities	35,102	34,800	14,179
Investing activities
Purchases of property and equipment	(4,882)	(2,982)	(3,761)
Proceeds from sale of building	0	2,023	0
Payments related to acquisitions	0	(72,627)	(21,240)
Purchases of short-term marketable securities	(59,194)	(2,205)	(22,699)
Proceeds from sales of marketable securities	3,000	22,900	23,600
Net cash used in investing activities	(61,076)	(52,891)	(24,100)
Financing activities
Payment of deferred acquisition consideration	(401)	(2,800)	(2,059)
Proceeds from revolving line of credit	0	25,000	0
Proceeds from issuance of long-term debt	0	40,000	0
Payments of revolving line of credit	0	(25,000)	0
Payments of long-term debt	(39,000)	(1,000)	0
Payment of deferred debt issuance costs	0	(1,751)	0
Proceeds from issuance of common stock	63,241	5,971	4,856
Purchase of treasury stock for net settlement of equity awards	(802)	(570)	(683)
Common stock cash dividend paid	(9,336)	(7,695)	(6,736)
Net cash provided by (used in) financing activities	13,702	32,155	(4,622)
Effect of exchange rate changes on cash and cash equivalents	(637)	914	11
Net increase (decrease) in cash and cash equivalents	(12,909)	14,978	(14,532)
Cash and cash equivalents at beginning of year	26,764	11,786	26,318
Cash and cash equivalents at end of year	$ 13,855	$ 26,764	$ 11,786

Note 9 - Income Taxes - Deferred Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Inventory	$ 2,231	$ 1,629
Net operating loss carryforwards	1,153	1,348
Tax credit carryforwards	1,033	1,019
Capital loss carryforwards	492	521
Reserves and accruals	712	994
Operating lease liabilities	3,562	3,664
Intangible assets	4,426	4,386
Stock options	440	359
Other	140	105
Total deferred tax assets	14,189	14,025
Deferred tax liabilities:
Property and equipment	(1,713)	(1,831)
Goodwill	(4,825)	(4,055)
Operating lease right-of-use assets	(3,355)	(3,503)
Foreign branch deferred offset	(843)	(954)
Other	(213)	(299)
Total deferred tax liabilities	(10,949)	(10,642)
Net deferred tax assets before valuation allowance	3,240	3,383
Valuation allowance	(1,744)	(1,824)
Net deferred tax liabiltity	1,496	1,559
Deferred tax classification
Deferred tax assets	1,566	1,686
Long-term deferred tax liability	(70)	(127)
Net long-term deferred tax asset	$ (1,496)	$ (1,559)

Note 11 - Profit-sharing Plan (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Defined Contribution, Plan Employers Matching Contribution, Annual Vesting Period (Year)	6 years
Deferred Profit Sharing [Member]
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0.5	$ 0.3	$ 0.4

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]	Total
Balance (in shares) at Dec. 31, 2018	21,110,224				1,501,511
Balance at Dec. 31, 2018	$ 211	$ 98,442	$ 45,831	$ (3,900)	$ (10,349)	$ 130,235
Net income			17,934			17,934
Other comprehensive income (loss)				(107)		$ (107)
Issuance of common stock for stock options exercised (in shares)	509,693					509,693
Issuance of common stock for stock options exercised	$ 6	4,850				$ 4,856
Vested restricted stock units (in shares)	59,010
Vested restricted stock units	$ 0	0				0
Stock-based compensation expense		2,642				2,642
Repurchase of common stock for net settlement of equity awards (in shares)					20,524
Repurchase of common stock for net settlement of equity awards					$ (683)	(683)
Common stock cash dividend paid			(6,736)			(6,736)
Repurchase of common stock for net settlement of equity awards					$ (683)	(683)
Balance (in shares) at Dec. 31, 2019	21,678,927				1,522,035
Balance at Dec. 31, 2019	$ 217	105,934	57,029	(4,007)	$ (11,032)	148,141
Net income			21,220			21,220
Other comprehensive income (loss)				2,482		$ 2,482
Issuance of common stock for stock options exercised (in shares)	331,958					331,958
Issuance of common stock for stock options exercised	$ 3	5,968				$ 5,971
Vested restricted stock units (in shares)	50,669
Vested restricted stock units	$ 1	0				1
Stock-based compensation expense		3,022				3,022
Repurchase of common stock for net settlement of equity awards (in shares)					16,537
Repurchase of common stock for net settlement of equity awards					$ (570)	(570)
Common stock cash dividend paid			(7,695)			(7,695)
Repurchase of common stock for net settlement of equity awards					$ (570)	(570)
Balance (in shares) at Dec. 31, 2020	22,061,554				1,538,572
Balance at Dec. 31, 2020	$ 221	114,924	70,554	(1,525)	$ (11,602)	172,572
Net income			26,907			26,907
Other comprehensive income (loss)				(1,910)		$ (1,910)
Issuance of common stock for stock options exercised (in shares)	217,121					217,121
Issuance of common stock for stock options exercised	$ 2	4,544				$ 4,546
Vested restricted stock units (in shares)	49,109
Vested restricted stock units	$ 0	0				0
Stock-based compensation expense		3,479				3,479
Repurchase of common stock for net settlement of equity awards (in shares)					16,333
Repurchase of common stock for net settlement of equity awards					$ (802)	(802)
Common stock cash dividend paid			(9,336)			(9,336)
Issuance of common stock, net of issuance costs (in shares)	1,150,000
Issuance of common stock, net of issuance costs	$ 12	58,683				58,695
Repurchase of common stock for net settlement of equity awards					$ (802)	(802)
Balance (in shares) at Dec. 31, 2021	23,477,784				1,554,905
Balance at Dec. 31, 2021	$ 235	$ 181,630	$ 88,125	$ (3,435)	$ (12,404)	$ 254,151

Note 12 - Segment and Enterprise-wide Disclosures - Net Sales to Unaffiliated Customers by Geography (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Net sales	$ 39,503	$ 38,368	$ 40,670	$ 35,883	$ 37,548	$ 36,416	$ 24,851	$ 30,551	$ 154,424	$ 129,366	$ 117,232
UNITED STATES
Net sales									93,866	75,222	63,130
GERMANY
Net sales									12,968	12,365	12,400
Other Countries [Member]
Net sales									$ 47,590	$ 41,779	$ 41,702

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Note 3 - Inventories and Other Deferred Costs (Tables)

12 Months Ended

Dec. 31, 2021

Notes Tables

Schedule of Inventory, Current [Table Text Block]

	December 31, 2021		December 31, 2020
	(in thousands)
Raw materials	$	5,945	$	5,044
Work-in-process		9,416		6,004
Finished products		25,286		28,117
Other deferred costs		5,457		5,950

Total inventory and other deferred costs	$	46,104	$	45,115

Note 4 - Property and Equipment - Depreciation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Depreciation expense	$ 3,280	$ 3,181	$ 2,979

Note 9 - Income Taxes - Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash paid for income taxes, net	$ 10,147	$ 4,470	$ 4,817

Note 12 - Segment and Enterprise-wide Disclosures - Long-term Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Long-term Assets	$ 32,130	$ 31,102
UNITED STATES
Long-term Assets	28,402	27,660
FRANCE
Long-term Assets	1,038	1,140
GERMANY
Long-term Assets	781	1,138
Other Countries [Member]
Long-term Assets	$ 1,909	$ 1,164

Note 7 - Accrued Expenses and Other Long-term Liabilities (Tables)

12 Months Ended

Dec. 31, 2021

Notes Tables

Schedule of Accrued Liabilities [Table Text Block]

	December 31, 2021		December 31, 2020
	(in thousands)
Compensation and related taxes	$	10,236	$	8,675
Income and other taxes		551		2,394
Professional fees		129		39
Other		5,416		6,417

Total	$	16,332	$	17,525

Other Noncurrent Liabilities [Table Text Block]

	December 31, 2021		December 31, 2020
	(in thousands)
Acquisition-related liabilities	$	1,761	$	3,700
Income taxes		799		813
Other		141		130

Total	$	2,701	$	4,643

Note 1 - Significant Accounting Policies and Related Matters - Allowance for Doubtful Accounts and Sales Returns (Details) - Allowance for Doubtful Accounts and Sales Returns [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Balance	$ 623	$ 522	$ 399
Additions (recoveries) charged to income	263	293	388
Deductions from reserves	207	192	265
Balance	$ 679	$ 623	$ 522

Note 9 - Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Unrecognized tax benefits at the beginning of year	$ 820	$ 848	$ 711
Additions/adjustments for tax positions of current year	0	0	74
Additions/adjustments for tax positions of prior years	(52)
Additions/adjustments for tax positions of prior years		37	63
Reductions for settlements with taxing authorities.	0	(65)	0
Reductions for lapses of the applicable statutes of limitations	0	0	0
Unrecognized tax benefits at the end of the year	$ 768	$ 820	$ 848

Note 10 - Stockholders' Equity - Stock-based Compensation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Stock-based compensation	$ 3,479	$ 3,022	$ 2,642
Cost of Sales [Member]
Stock-based compensation	407	333	310
Sales [Member]
Stock-based compensation	527	516	544
General and Administrative Expense [Member]
Stock-based compensation	2,185	1,883	1,509
Research and Development Expense [Member]
Stock-based compensation	360	290	279
Share-based Payment Arrangement, Option [Member]
Stock-based compensation	2,199	1,938	1,580
Restricted Stock Units (RSUs) [Member]
Stock-based compensation	1,247	1,084	1,062
Performance Shares [Member]
Stock-based compensation	$ 33	$ 0	$ 0

Note 1 - Significant Accounting Policies and Related Matters (Tables)

12 Months Ended

Dec. 31, 2021

Notes Tables

Disaggregation of Revenue [Table Text Block]

	Year ended December 31,
	2021		2020
Americas	$	102,265	$	81,470
Europe, Middle East and Africa		42,132		39,193
Asia Pacific		10,027		8,703
Total	$	154,424	$	129,366

Schedule of Advertising Expenses [Table Text Block]

	Year ended December 31,
	2021		2020		2019
			(in thousands)

Advertising expense	$	236	$	216	$	286

Financing Receivable, Allowance for Credit Loss [Table Text Block]

	Balance at		Additions		Deductions		Balance at
	Beginning		(recoveries) charged		from		End of
	of Period		to Income		Reserves		Period
	(in thousands)
Allowance for doubtful accounts and sales returns:
Year ended December 31, 2021	$	623	$	263	$	207	$	679
Year ended December 31, 2020		522		293		192		623
Year ended December 31, 2019		399		388		265		522

Schedule of Property, Plant and Equipment Estimated Useful Lives [Table Text Block]

Description	Useful Life (in years)
Computers and equipment	3	–	5
Machinery and equipment	3	–	10
Leasehold improvements	The shorter of its useful life or lease term

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Year ended December 31,
	2021		2020		2019
		(in thousands, except per share data)
Basic:
Net income available for common stockholders	$	26,907	$	21,220	$	17,934
Weighted average shares outstanding		21,157		20,246		19,813

Basic earnings per share	$	1.27	$	1.05	$	0.91

Net income available for common stockholders	$	26,907	$	21,220	$	17,934
Weighted-average shares outstanding		21,157		20,246		19,813
Common stock equivalents, if dilutive		318		233		513
Shares used in computing diluted earnings per common share		21,475		20,479		20,326

Diluted earnings per share	$	1.25	$	1.04	$	0.88

Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive		10		483		468

Note 1 - Significant Accounting Policies and Related Matters - Disaggregation of Revenue by Major Geographic Area (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue	$ 154,424	$ 129,366
Americas [Member]
Revenue	102,265	81,470
EMEA [Member]
Revenue	42,132	39,193
Asia Pacific [Member]
Revenue	$ 10,027	$ 8,703

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Note 14 - Accumulated Other Comprehensive Income (Loss) (Tables)

12 Months Ended

Dec. 31, 2021

Notes Tables

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

	Year ended December 31,
	2021			2020			2019
	(in thousands)
Beginning balance	$	(1,525	)	$	(4,007	)	$	(3,900	)

Other comprehensive income (loss) before reclassifications		(1,910	)		2,482			(107	)
Amounts reclassified from accumulated other comprehensive loss		-			-			-

Ending Balance	$	(3,435	)	$	(1,525	)	$	(4,007	)

Note 12 - Segment and Enterprise-wide Disclosures (Details Textual)	1 Months Ended	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2021
Number of Operating Segments	1	1

Note 3 - Inventories and Other Deferred Costs

12 Months Ended

Dec. 31, 2021

Notes to Financial Statements

Inventory and Other Deferred Costs Disclosure [Text Block]

3. Inventory and Other Deferred Costs

Inventory and other deferred costs consists of the following:

	December 31, 2021		December 31, 2020
	(in thousands)
Raw materials	$	5,945	$	5,044
Work-in-process		9,416		6,004
Finished products		25,286		28,117
Other deferred costs		5,457		5,950

Total inventory and other deferred costs	$	46,104	$	45,115

We had inventory on consignment at customer sites of $2.1 million as of both December 31, 2021 and 2020.

In connection with our RestoreFlow allograft business, other deferred costs include costs incurred for the preservation of human vascular tissues available for shipment, tissues currently in active processing, and tissues held in quarantine pending release to implantable status. By federal law, human tissues cannot be bought or sold. Therefore, the tissues we preserve are not held as inventory, and the costs we incur to procure and process vascular tissues are instead accumulated and deferred. These costs include fixed and variable overhead costs associated with the cryopreservation process, including primarily direct labor costs, tissue recovery fees, inbound freight charges, indirect materials and facilities costs. General and administrative expenses and selling expenses associated with the provision of these services are expensed as incurred.

Note 3 - Inventories and Other Deferred Costs - Summary of Inventories and Other Deferred Costs (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Raw materials	$ 5,945	$ 5,044
Work-in-process	9,416	6,004
Finished products	25,286	28,117
Other deferred costs	5,457	5,950
Total inventory and other deferred costs	$ 46,104	$ 45,115

Note 15 - Quarterly Financial Data (Unaudited) - Quarterly Financial Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Total net sales	$ 39,503	$ 38,368	$ 40,670	$ 35,883	$ 37,548	$ 36,416	$ 24,851	$ 30,551	$ 154,424	$ 129,366	$ 117,232
Gross profit	25,956	24,866	26,761	23,799	24,402	22,704	17,029	20,483	101,382	84,618	79,853
Income from operations	8,301	9,073	11,106	7,945	9,545	10,018	4,872	4,353	36,425	28,788	21,183
Net income	$ 6,175	$ 6,504	$ 8,299	$ 5,929	$ 7,033	$ 7,513	$ 3,500	$ 3,174	$ 26,907	$ 21,220	$ 17,934
Basic:
Basic (in dollars per share)	$ 0.28	$ 0.30	$ 0.40	$ 0.29	$ 0.35	$ 0.37	$ 0.17	$ 0.16	$ 1.27	$ 1.05	$ 0.91
Diluted (in dollars per share)	$ 0.28	$ 0.30	$ 0.40	$ 0.28	$ 0.34	$ 0.37	$ 0.17	$ 0.16	$ 1.25	$ 1.04	$ 0.88
Total net sales	$ 39,503	$ 38,368	$ 40,670	$ 35,883	$ 37,548	$ 36,416	$ 24,851	$ 30,551	$ 154,424	$ 129,366	$ 117,232
Gross profit	25,956	24,866	26,761	23,799	24,402	22,704	17,029	20,483	101,382	84,618	79,853
Income from operations	8,301	9,073	11,106	7,945	9,545	10,018	4,872	4,353	36,425	28,788	21,183
Net income	$ 6,175	$ 6,504	$ 8,299	$ 5,929	$ 7,033	$ 7,513	$ 3,500	$ 3,174	$ 26,907	$ 21,220	$ 17,934

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Net income	$ 26,907	$ 21,220	$ 17,934
Other comprehensive income (loss):
Foreign currency translation adjustment, net	(1,604)	2,468	(234)
Unrealized gain (loss) on short-term marketable securities	(306)	14	127
Total other comprehensive income (loss)	(1,910)	2,482	(107)
Comprehensive income	$ 24,997	$ 23,702	$ 17,827

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Note 13 - Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2021

Notes Tables

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	Year ended December 31,
	2021			2020		2019
	(in thousands)
Beginning balance	$	2,240		$	1,764	$	72
Additions		-			406		1,989
Payments		-			-		(309	)
Change in fair value included in earnings		(748	)		70		12

Ending balance	$	1,492		$	2,240	$	1,764

Note 5 - Goodwill and Other Intangible Assets - Estimated Amortization Expense for Each of Five Succeeding Fiscal Years (Details) $ in Thousands	Dec. 31, 2021 USD ($)
2022	$ 6,016
2023	5,884
2024	5,702
2025	5,464
2026	$ 4,997

Note 4 - Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2021

Notes Tables

Property, Plant and Equipment [Table Text Block]

	As of December 31,
	2021			2020
	(in thousands)
Computers and equipment	$	5,667		$	5,046
Machinery and equipment		18,439			17,266
Building and leasehold improvements		15,884			12,809

Gross property and equipment		39,990			35,121
Less accumulated depreciation		(22,931	)		(20,085	)

Property and equipment, net	$	17,059		$	15,036

Depreciation Expense [Table Text Block]

	Year ended December 31,
	2021		2020		2019
			(in thousands)

Depreciation expense	$	3,280	$	3,181	$	2,979

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Description of Business

Consolidation, Policy [Policy Text Block]

Consolidation and Basis of Presentation

Our consolidated financial statements include the accounts of LeMaitre Vascular and the accounts of our wholly-owned subsidiaries, LeMaitre Vascular GmbH, LeMaitre Vascular GK, Vascutech Acquisition LLC, LeMaitre Acquisition LLC, LeMaitre Vascular SAS, LeMaitre Vascular S.r.l., LeMaitre Vascular Spain SL, LeMaitre Vascular Switzerland GmbH, LeMaitre Vascular ULC, LeMaitre Vascular AS, LeMaitre Vascular Pty Ltd, Bio Nova International Pty Ltd, LeMaitre Vascular, Ltd., LeMaitre Medical Technology (Shanghai) Co. Ltd, LeMaitre Cardial SAS and LeMaitre Pte Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation.

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Foreign Currency Translation

Balance sheet accounts of foreign subsidiaries are translated into U.S. dollars at year-end exchange rates. Operating accounts are translated at average exchange rates for each year. Net translation gains or losses are adjusted directly to a separate component of other comprehensive income (loss) within stockholders’ equity. Foreign exchange transaction gains (losses), substantially all of which relate to intercompany activity between us and our foreign subsidiaries, are included in other income (expense) in the accompanying consolidated statements of operations.

Use of Estimates, Policy [Policy Text Block]

Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in in our consolidated financial statements and accompanying notes. Due to the COVID-19 pandemic, there is heightened volatility and uncertainty in customer demand and the worldwide economy in general. However, the magnitude and duration of the impact on our revenues and operations from COVID-19 is uncertain and cannot currently be reasonably estimated at this time. The Company is not aware of any specific event or circumstance that would require an update to its accounting estimates or adjustments to the carrying value of its assets and liabilities as of February 28, 2022, the issuance date of this Annual Report on Form 10-K. Actual results could differ from those estimates, particularly if the Company experiences material impacts to the carrying value of its assets and liabilities from COVID-19.

Revenue from Contract with Customer [Policy Text Block]

Revenue Recognition

Our revenue is derived primarily from the sale of disposable or implantable devices used during vascular surgery. We sell primarily directly to hospitals and to a lesser extent to distributors, as described below, and, during the periods presented in our consolidated financial statements, entered into consigned inventory arrangements with either hospitals or distributors on a limited basis. With the acquisition of the RestoreFlow allograft business, we also derive revenues from the processing and cryopreservation of human tissues for implantation in patients. These revenues are recognized when services have been provided and the tissue has been shipped to the customer, provided all other revenue recognition criteria discussed in the succeeding paragraph have been met.

We record revenue under the provisions of ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The core principle of Topic 606 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard explains that to achieve the core principle, an entity should take the following actions:

Step 1: Identify the contract with a customer

Step 2: Identify the performance obligations in the contract

Step 3: Determine the transaction price

Step 4: Allocate the transaction price

Step 5: Recognize revenue when or as the entity satisfies a performance obligation

Revenue is recognized when or as a company satisfies a performance obligation by transferring a promised good or service to a customer (which is when the customer obtains control of that good or service). In instances in which shipping and handling activities are performed after a customer takes control of the goods (such as when title passes upon shipment from our dock), we have made the policy election allowed under Topic 606 to account for these activities as fulfillment costs and not as performance obligations.

We generally reference customer purchase orders to determine the existence of a contract. Orders that are not accompanied by a purchase order are confirmed with the customer either in writing or verbally. The purchase orders or similar correspondence, once accepted, identify the performance obligations as well as the transaction price, and otherwise outline the rights and obligations of each party. We allocate the transaction price of each contract among the performance obligations in accordance with the pricing of each item specified on the purchase order, which is in turn based on standalone selling prices per our published price lists. In cases where we discount products or provide certain items free of charge, we allocate the discount proportionately to all performance obligations, unless it can be demonstrated that the discount should be allocated entirely to one or more, but not all, of the performance obligations.

We record revenue, net of allowances for returns and discounts, fees paid to group purchasing organizations, and any sales and value added taxes required to be invoiced, which we have elected to exclude from the measurement of the transaction price as allowed by the standard, at the time of shipment (taking into consideration contractual shipping terms), or in the case of consigned inventory, when it is consumed. Shipment is the point at which control of the product and title passes to our customers, and at which LeMaitre has a present right to receive payment for the goods.

Below is a disaggregation of our revenue by major geographic area, which is among the primary categorizations used by management in evaluating financial performance, for the periods indicated (in thousands):

	Year ended December 31,
	2021		2020
Americas	$	102,265	$	81,470
Europe, Middle East and Africa		42,132		39,193
Asia Pacific		10,027		8,703
Total	$	154,424	$	129,366

We do not carry any contract assets or contract liabilities, as there are generally no unbilled amounts due from customers under contracts for which we have partially satisfied performance obligations, or amounts received from customers for which we have not satisfied performance obligations. We satisfy our performance obligations under revenue contracts within a very short time period from receipt of the orders, and payments from customers are typically received within 30 to 60 days of fulfillment of the orders, except in certain geographies such as Spain and Italy where the payment cycle is customarily longer. Accordingly, there is no significant financing component to our revenue contracts. Additionally, we have elected as a policy that incremental costs (such as commissions) incurred to obtain contracts are expensed as incurred, due to the short-term nature of the contracts.

Customers returning products may be entitled to full or partial credit based on the condition and timing of the return. To be accepted, a returned product must be unopened (if sterile), unadulterated, and undamaged, must have at least 18 months remaining prior to its expiration date, or twelve months for our hospital customers in Europe, and generally be returned within 30 days of shipment. These return policies apply to sales to both hospitals and distributors. The amount of products returned to us, either for exchange or credit, has not been material. Nevertheless, we provide for an allowance for future sales returns based on historical return experience, which requires judgment. Our cost of replacing defective products has not been material and is accounted for at the time of replacement.

Research and Development Expense, Policy [Policy Text Block]

Research and Development Expense

Research and development costs, principally salaries, laboratory testing, and supplies, are expensed as incurred and also include royalty payments associated with licensed and acquired intellectual property.

Shipping and Handling [Policy Text Block]

Shipping and Handling Costs

Shipping and handling fees paid by customers are recorded within net sales, with the related expense recorded in cost of sales.

Advertising Cost [Policy Text Block]

Advertising Costs

Advertising costs are expensed as incurred and are included as a component of sales and marketing expense in the accompanying consolidated statements of operations. Advertising costs are as follows:

	Year ended December 31,
	2021		2020		2019
			(in thousands)

Advertising expense	$	236	$	216	$	286

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

We consider all highly liquid instruments purchased with maturity dates of 90 days or less to be cash equivalents. Cash and cash equivalents are primarily invested in money market funds. These amounts are stated at cost, which approximates fair value.

Marketable Securities, Policy [Policy Text Block]

Short-term Marketable Securities

Our short-term marketable securities are available-for-sale securities carried at fair value, with unrealized gains and losses recorded in other comprehensive income. They include a managed income mutual fund investing mainly in short-term investment-grade, U.S. dollar denominated fixed and floating rate debt, and a short-duration bond fund.

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentrations of Credit Risk

Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Cash equivalents represent highly liquid investments with maturities of 90 days or less at the date of purchase. Credit risk related to cash and cash equivalents are limited based on the creditworthiness of the financial institutions at which these funds are held. We maintain cash balances in several banks. Accounts located in the United States are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. Certain of our account balances exceed the FDIC limit. Cash balances held outside the United States totaled approximately $9.4 million as of December 31, 2021.

Our accounts receivable are with customers based in the United States and internationally. Accounts receivable generally are due within 30 to 90 days of invoice and are stated at amounts due from customers, net of an allowance for doubtful accounts and sales returns, other than in certain European markets where longer payment terms are customary and may range from 90 to 240 days. We perform ongoing credit evaluations of the financial condition of our customers and adjust credit limits based upon payment history and the current creditworthiness of the customers, as determined by a review of their current credit information. We continuously monitor aging reports, collections, and payments from customers, and maintain a provision for estimated credit losses based upon historical experience and any specific customer collection issues we identify.

We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our European sales to government-owned or supported customers such as hospitals, distributors and agents, particularly in Italy and Spain, may be subject to significant payment delays due to government austerity measures impacting funding and payment practices. As of December 31, 2021 our receivables in Italy and Spain totaled $1.0 million and $0.7 million, respectively. Receivables balances with certain government-owned hospitals and government supported customers in these countries can accumulate over a period of time and then subsequently be settled as large lump sum payments. While we believe our allowance for doubtful accounts in these countries is adequate as of December 31, 2021, if significant changes were to occur in the payment practices of these European governments or if government funding becomes unavailable, we may not be able to collect on receivables due to us from these customers and our write offs of uncollectible amounts may increase.

We write off accounts receivable when they become uncollectible. Such credit losses have historically been within our expectations and allowances. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable. We review our allowance for doubtful accounts on a monthly basis and all past due balances are reviewed individually for collectability. The provision for the allowance for doubtful accounts is recorded in general and administrative expenses. The following is a summary of our allowance for doubtful accounts and sales returns:

	Balance at		Additions		Deductions		Balance at
	Beginning		(recoveries) charged		from		End of
	of Period		to Income		Reserves		Period
	(in thousands)
Allowance for doubtful accounts and sales returns:
Year ended December 31, 2021	$	623	$	263	$	207	$	679
Year ended December 31, 2020		522		293		192		623
Year ended December 31, 2019		399		388		265		522

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

Our financial instruments include cash and cash equivalents, short-term marketable securities, accounts receivable and trade payables. The fair value of these instruments approximates their carrying value based upon their short-term nature or variable rates of interest. Unrealized gains and losses on our short-term marketable securities are recorded in other comprehensive income and were not material to our consolidated financial statements for the year ended December 31, 2021.

Inventory and Other Deferred Costs [Policy Text Block]

Inventory and Other Deferred Costs

Inventory and Other Deferred Costs consists of finished products, work-in-process, raw materials and costs deferred in connection with human tissue cryopreservation services of our RestoreFlow allograft business. We value inventory and other deferred costs at the lower of cost or market value. Cost includes materials, labor and manufacturing overhead and is determined using the first-in, first-out (FIFO) method. On a quarterly basis, we review inventory quantities on hand and analyze the provision for excess and obsolete inventory based primarily on product expiration dating and our estimated sales forecast, which is based on sales history and anticipated future demand. Our estimates of future product demand may not be accurate, and we may understate or overstate the provision required for excess and obsolete inventory. Accordingly, any significant unanticipated changes in demand could have a significant impact on the value of our inventory and results of operations.

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

Property and equipment are recorded at cost. Depreciation is provided over the estimated useful lives of the related assets using straight-line method as follows:

Description	Useful Life (in years)
Computers and equipment	3	–	5
Machinery and equipment	3	–	10
Leasehold improvements	The shorter of its useful life or lease term

Expenditures for maintenance and repairs are charged to operations when incurred, while additions and betterments are capitalized. When assets are retired or disposed, the asset’s original cost and related accumulated depreciation are eliminated from the accounts and any gain or loss is reflected in the statement of operations.

Business Combinations Policy [Policy Text Block]

Valuation of Business Combinations

We assign the value of the consideration transferred to acquire a business to the tangible assets and identifiable intangible assets acquired and liabilities assumed on the basis of their fair values at the date of acquisition. We assess the fair value of assets, including intangible assets, using a variety of methods and are usually performed by an independent appraiser who measures fair value from the perspective of a market participant.

Acquisitions have been accounted for using the acquisition method, and the acquired companies’ results have been included in the accompanying consolidated financial statements from their respective dates of acquisition. Acquisition transaction costs have been recorded in general and administrative expenses, and are expensed as incurred. Allocation of the purchase price for acquisitions is based on estimates of the fair value of the net assets acquired and, for acquisitions completed within the past year, is subject to adjustment upon finalization of the purchase price allocation.

Our acquisitions have historically been made at prices above the fair value of the acquired assets, resulting in goodwill, due to expectations of synergies of combining the businesses. These synergies include use of our existing commercial infrastructure to expand sales of the acquired businesses’ products, use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of our products, and the elimination of redundant facilities, functions and staffing.

Contingent Consideration [Policy Text Block]

Contingent Consideration

Contingent consideration for acquisitions is recognized at the date of acquisition, based on the fair value at that date, and then re-measured periodically through adjustments to net income.

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Impairment of Long-lived Assets

We review our long-lived assets (primarily property and equipment and intangible assets) subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall, or an adverse action or assessment by a regulator. If an impairment indicator exists, we test the intangible asset for recoverability. We record impairment losses on long-lived assets used in operations when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. Impairment is measured based on the fair market value of the affected asset using discounted cash flows.

Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]

Goodwill

Goodwill represents the amount of consideration paid in connection with business acquisitions in excess of the fair value of assets acquired and liabilities assumed. Goodwill is evaluated for impairment annually, or more frequently if indicators of impairment are present or changes in circumstances suggest that an impairment may exist. We evaluate the December 31 balance of the carrying value of goodwill based on a single reporting unit annually. We perform an assessment of qualitative factors to determine if it is “more likely than not” that the fair value of our reporting unit is less than its carrying value as a basis for determining whether it is necessary to perform the quantitative goodwill impairment test. The “more likely than not” threshold is defined as having a likelihood of more than 50 percent. The quantitative goodwill impairment test compares the fair value of a reporting unit with its carrying amount, including goodwill. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired. If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit. We have determined that no goodwill impairment charges were required for the years ended December 31, 2021, 2020 or 2019.

Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]

Other Intangible Assets

Other intangible assets consist primarily of patents, trademarks, technology licenses, and customer relationships acquired in connection with business acquisitions and asset acquisitions and are amortized over their estimated useful lives, ranging from 2 to 16 years.

Share-based Payment Arrangement [Policy Text Block]

Stock-based Compensation

We recognize, as expense, the estimated fair value of stock options to employees determined using the Black-Scholes option pricing model. Share-based compensation charges are recorded across the consolidated statement of operations based upon the grantee’s primary function. We have elected to recognize the compensation cost of all share-based awards on a straight-line basis over the vesting period of the award. In periods that we grant stock options, fair value assumptions are based on volatility, interest, dividend yield, and expected term over which the stock options will be outstanding. The computation of expected volatility is based on the historical volatility of the company’s stock. The interest rate for periods within the contractual life of the award is based on the U.S. Treasury risk-free interest rate in effect at the time of grant. Historical data on exercise patterns is the basis for estimating the expected life of an option. The expected annual dividend rate was calculated by dividing our annual dividend, based on the most recent quarterly dividend rate, by the closing stock price on the grant date.

We also issue restricted stock units (RSUs) and performance-based restricted stock units (PSUs) as additional forms of equity compensation to our employees, officers, and directors, pursuant to our stockholder-approved 2006 Plan. RSUs entitle the grantee to an issuance of stock at no cost and generally vest over a period of time determined by our Board of Directors at the time of grant. PSUs awarded in 2021 will vest based on achievement of operating income for 2021 against budgeted operating income as approved by our Board of Directors. The fair market value of the award is determined based on the number of RSUs and PSUs granted and the market value of our common stock on the grant date and is amortized to expense over the period of vesting. Unvested RSUs and PSUs are forfeited and canceled as of the date that employment or service to the company terminates. RSUs and PSUs are settled in shares of our common stock upon vesting. We typically repurchase common stock upon our employees’ vesting in RSUs and PSUs in order to cover any minimum tax withholding liability as a result of the awards having vested.

Commitments and Contingencies, Policy [Policy Text Block]

Commitments and Contingencies

In the normal course of business, we are subject to proceedings, lawsuits, and other claims and assessments for matters related to, among other things, patent infringement, business acquisitions, employment, commercial matters and product recalls. We assess the likelihood of any adverse judgments or outcomes to these matters as well as potential ranges of probable losses. A determination of the amount of reserves required, if any, for these contingencies is made after careful analysis of each individual issue. The required reserves may change in the future due to new developments or changes in approach, such as a change in settlement strategy in dealing with each matter. We record charges for anticipated losses in connection with litigation and claims against us when we conclude a loss is probable and we can reasonably estimate the loss. During the years ended December 31, 2021, 2020 and 2019, we were not subject to any material litigation or claims and assessments.

Sales of medical devices outside the U.S. are subject to international regulatory requirements that vary from country to country. These requirements and the amount of time required for approval may differ from our experiences with the U.S. FDA. In the European Union we are required to obtain CE marks for our products, which denote conformity to essential requirements for manufacturers of higher-risk devices. Failure to obtain, retain or maintain these CE marks would impact our ability to sell our products in certain European countries and could cause our business to suffer. There can be no assurance that we will be able to obtain or maintain the required regulatory approvals in these countries.

Income Tax, Policy [Policy Text Block]

Income Taxes

We account for income taxes under the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred taxes are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The provision for income taxes includes taxes currently payable and deferred taxes resulting from the tax effects of temporary differences between the financial statement and tax bases of assets and liabilities. We maintain valuation allowances where it is more likely than not that all or a portion of a deferred tax asset will not be realized. Changes in the valuation allowances are included in our tax provision in the period of change. In determining whether a valuation allowance is warranted, we evaluate factors such as prior earnings history, expected future earnings, carry-back and carry-forward periods and tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset.

We recognize, measure, present and disclose in our financial statements, uncertain tax positions that we have taken or expect to take on a tax return. We recognize in our financial statements the impact of tax positions that meet a “more likely than not” threshold, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement.

Our policy is to classify interest and penalties related to unrecognized tax benefits as income tax expense.

Comprehensive Income, Policy [Policy Text Block]

Comprehensive Income

Comprehensive income is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other than reported net income, comprehensive income includes foreign currency translation adjustments and unrealized gains and losses on our marketable securities, which are disclosed in the accompanying consolidated statements of comprehensive income. There were no reclassifications out of comprehensive income for the years ended December 31, 2021, 2020 or 2019.

Accumulated other comprehensive loss consisted primarily of foreign currency translation adjustment losses of $3.1 million and $1.6 million as of December 31, 2021 and 2020, respectively.

Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]

Restructuring

We record restructuring charges incurred in connection with consolidation or relocation of operations, exited business lines, reductions in force, or distributor terminations. These restructuring charges, which reflect our commitment to a termination or exit plan that will begin within twelve months, are based on estimates of the expected costs associated with site closure, legal matters, contract terminations, severance payments, or other costs directly related to the restructuring. If the actual cost incurred exceeds the estimated cost, an additional charge to earnings will result. If the actual cost is less than the estimated cost, a credit to earnings will be recognized.

Earnings Per Share, Policy [Policy Text Block]

Earnings per Share

We compute basic earnings per share by dividing net income available for common stockholders by the weighted average number of shares outstanding during the year. Except where the result would be anti-dilutive to net income per share, diluted earnings per share has been computed using the treasury stock method and reflects the potential vesting of restricted common stock and the potential exercise of stock options, as well as their related income tax effects.

The computation of basic and diluted net income per share is as follows:

	Year ended December 31,
	2021		2020		2019
		(in thousands, except per share data)
Basic:
Net income available for common stockholders	$	26,907	$	21,220	$	17,934
Weighted average shares outstanding		21,157		20,246		19,813

Basic earnings per share	$	1.27	$	1.05	$	0.91

Net income available for common stockholders	$	26,907	$	21,220	$	17,934
Weighted-average shares outstanding		21,157		20,246		19,813
Common stock equivalents, if dilutive		318		233		513
Shares used in computing diluted earnings per common share		21,475		20,479		20,326

Diluted earnings per share	$	1.25	$	1.04	$	0.88

Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive		10		483		468

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

In December 2019, the FASB issued ASU 2019-12 Income Taxes (Topic 740), which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 as well as clarifying and amending other areas of existing GAAP under Topic 740. The new standard was effective for us beginning January 1, 2021, and adoption of this standard did not have a material impact on our financial statements.

Note 14 - Accumulated Other Comprehensive Income (Loss) - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Balance	$ 172,572	$ 148,141	$ 130,235
Balance	254,151	172,572	148,141
AOCI Attributable to Parent [Member]
Balance	(1,525)	(4,007)	(3,900)
Other comprehensive income (loss) before reclassifications	(1,910)	2,482	(107)
Amounts reclassified from accumulated other comprehensive loss	0	0	0
Balance	$ (3,435)	$ (1,525)	$ (4,007)

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

Note 2 - Acquisitions - Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Jun. 22, 2020	Dec. 31, 2019	Oct. 11, 2019	Jul. 12, 2019
Goodwill	$ 65,945	$ 65,945		$ 39,951
Artegraft Inc [Member]
Inventory			$ 3,859
Accounts receivable			1,789
Equipment and supplies			1,140
Accounts payable and other			53
Intangible assets			39,056
Goodwill			27,115
Purchase price			72,906
Equipmentand supplies			$ 1,140
CardioCel and VascuCel Biologic Patches [Member]
Intangible assets					$ 8,725
Goodwill					5,999
Purchase price					17,412
Inventory and other					1,343
Deferred tax assets					$ 1,345
Tru-Incise Valve Cutter [Member]
Inventory						$ 276
Equipment and supplies						70
Intangible assets						4,844
Goodwill						2,748
Purchase price						7,938
Equipmentand supplies						$ 70

Note 1 - Significant Accounting Policies and Related Matters (Details Textual) $ in Thousands	1 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2021 USD ($)	Sep. 30, 2021	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Number of Operating Segments	1		1
Accounts Receivable, after Allowance for Credit Loss, Current, Total	$ 19,631		$ 19,631	$ 19,552
Goodwill, Impairment Loss			0	0	$ 0
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax			0	0	$ 0
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax, Ending Balance	3,100		3,100	$ 1,600
ITALY
Accounts Receivable, after Allowance for Credit Loss, Current, Total	1,000		1,000
SPAIN
Accounts Receivable, after Allowance for Credit Loss, Current, Total	700		700
Geographic Distribution, Foreign [Member]
Cash, Ending Balance	$ 9,400		$ 9,400
Minimum [Member]
Period of Payments Received from Customers (Day)		30 days
Finite-Lived Intangible Asset, Useful Life (Year)			2 years
Maximum [Member]
Period of Payments Received from Customers (Day)		60 days
Finite-Lived Intangible Asset, Useful Life (Year)			16 years

Note 12 - Segment and Enterprise-wide Disclosures

12 Months Ended

Dec. 31, 2021

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

12. Segment and Enterprise-wide Disclosures

The FASB establishes standards for reporting information regarding operating segments in financial statements. Operating segments are identified as components of an enterprise that engage in business activities for which separate, discrete financial information is available and is regularly reviewed by the chief operating decision-maker in making decisions on how to allocate resources and assess performance. We view our operations and manage our business as one operating segment. No discrete operating information is prepared by us except for sales by product line and operations by legal entity for local reporting purposes.

Most of our revenues are generated in the United States, Germany, and other European countries, Canada, the United Kingdom and Japan, and substantially all of our assets are located in the United States, Germany and France. Net sales to unaffiliated customers by country were as follows:

	Year ended December 31,
	2021		2020		2019
	(in thousands)

United States	$	93,866	$	75,222	$	63,130
Germany		12,968		12,365		12,400
Other countries		47,590		41,779		41,702

Net sales	$	154,424	$	129,366	$	117,232

Long-term assets by country, including property and equipment, net and right-of-use leased assets were as follows:

	As of December 31,
	2021		2020
	(in thousands)

United States	$	28,402	$	27,660
France		1,038		1,140
Germany		781		1,138
Other countries		1,909		1,164

Total long-term assets	$	32,130	$	31,102

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Note 8 - Commitments and Contingencies (Details Textual) $ in Thousands	Dec. 31, 2021 USD ($)	Jun. 30, 2021	Dec. 31, 2020 ft²
Finance Lease, Right-of-Use Asset \| $	$ 0
Lessee, Operating Lease, Discount Rate	5.25%
Purchase Obligation, Total \| $	$ 6,200
Senior Secured Credit Facility [Member] \| Term Loan [Member]
Debt Instrument, Interest Rate, Stated Percentage	3.50%
Leased Automobiles [Member]
Lessee, Operating Lease, Term of Contract (Year)	3 years
Leased Printing Equipment [Member]
Lessee, Operating Lease, Term of Contract (Year)		5 years
North Brunswick, New Jersey [Member] \| Artegraft Inc [Member]
Area of Real Estate Property (Square Foot)			16,732
ITALY \| Customer Service and Warehouse Facility [Member]
Lessee, Operating Lease, Renewal Term (Year)		6 years
Lessee, Operating Lease, Term of Contract (Year)		6 years
CANADA
Lessee, Operating Lease, Renewal Term (Year)		5 years
Principal Worldwide Executive, Distribution, and Manufacturing Operations Facilities [Member] \| Massachusetts [Member]
Area of Real Estate Property (Square Foot)			109,354
International Operations Headquarter Facility [Member] \| GERMANY
Area of Real Estate Property (Square Foot)			16,470
Lessee, Operating Lease, Renewal Term (Year)			5 years

Note 2 - Acquisitions

12 Months Ended

Dec. 31, 2021

Notes to Financial Statements

Business Combination Disclosure [Text Block]

2. Acquisitions and Divestitures

Acquisitions are accounted for using the acquisition method and the acquired businesses’ results have been included in the accompanying consolidated financial statements from their respective dates of acquisition. In each case for the acquisitions disclosed below, pro forma information assuming the acquisition had occurred at the beginning of the earliest period presented is not included as the impact is immaterial.

Our acquisitions have historically been made at prices above the fair value of the acquired identifiable assets, resulting in goodwill, due to expectations of synergies that will be realized by combining businesses. These synergies include the use of our existing sales channel to expand sales of the acquired businesses’ products, consolidation of manufacturing facilities, and the leveraging of our existing administrative infrastructure.

The fair market valuations associated with these transactions fall within Level 3 (see Note 13) of the fair value hierarchy, due to the use of significant unobservable inputs to determine fair value. The fair value measurements were calculated using unobservable inputs, primarily using the income approach, specifically the discounted cash flow method. The amount and timing of future cash flows within our analysis was based on our due diligence models, most recent operational budgets, long range strategic plans and other estimates.

Artegraft Biologic Grafts

On June 22, 2020, we entered into an Asset Purchase Agreement (Artegraft APA) to acquire the biologic graft business from Artegraft, Inc., who subsequent to the closing changed their name to Accidentals, Inc, (Artegraft, Inc.). Under the terms of the Artegraft APA, we agreed to pay Artegraft, Inc. a total of up to $90.0 million for the purchase of substantially all of its assets related to its business of the manufacturing, marketing, sale and distribution of its bovine carotid artery grafts (Products) other than specifically identified excluded assets. The acquired assets included inventory, accounts receivable, machinery and equipment, intellectual property, permits and approvals, data and records, and customer and supplier information. At closing, $72.5 million of the purchase price was paid to Artegraft, Inc. and other parties as specified in the Artegraft APA, including $7.5 million into an escrow account. The escrow amount was to be held until December 31, 2021 to cover any potential claims against LeMaitre or Artegraft, Inc. It has since been released to Artegraft, Inc. by mutual consent of the parties.

Three earn-out payments of $5,833,333 each are potentially due to Artegraft, Inc. under the Artegraft APA depending on the achievement of specified revenue targets, as follows:

●

$5.8 million upon final determination that 20,000 units of Product have been sold to third parties from January 1, 2021 to December 31, 2021 (this milestone was not met and accordingly no payment was made);

●

$5.8 million upon final determination that 24,000 units of Product have been sold to third parties from January 1, 2022 to December 31, 2022; and

●

$5.8 million upon final determination that 28,800 units of Product have been sold to third parties from January 1, 2023 to December 31, 2023.

The Artegraft APA includes a catch-up feature on the earn-outs such that, at the end of the three-year period, if the sum of the unit sales for all three years is greater than or equal to 58,240 unit sales (80% of the combined individual-year targets), Artegraft, Inc. will receive a “catch-up payment” in an amount equal to (a) $17,500,000 times a fraction, the numerator of which is the aggregate number of unit sales for the three-year period, and the denominator of which is 72,800 less (b) any individual-year earn-out previously paid. We recorded this liability at a fair value of $0.4 million to reflect management’s estimate of the likelihood of achieving these targets at the time of the closing of the acquisition, as well as the time value of money until payment. This amount will be remeasured each quarter during the earn-out period, with any adjustments recorded in income from operations.

On the date of acquisition, the Company allocated the consideration given to the individual assets acquired and the liabilities assumed based on a preliminary estimate of their fair values. During the three months ended September 30, 2020, the Company obtained and considered additional information related to the assets acquired and liabilities assumed, and recorded measurement period adjustments to the allocation of the purchase price. The following table summarizes the purchase price allocation:

	Allocated
	Fair Value
	(in thousands)
Inventory	$	3,859
Accounts receivable		1,789
Equipment and supplies		1,140
Accounts payable and other		(53	)
Intangible assets		39,056
Goodwill		27,115

Purchase price	$	72,906

The goodwill results from expected synergies of combining the acquired products and customer information to our existing operations, and is deductible for tax purposes over 15 years.

The following table reflects the allocation of purchase consideration to the acquired intangible assets and related estimated useful lives:

	Allocated		Estimated
	Fair Value		Useful Life (in years)
	(in thousands)
Customer relationships	$	20,310		15.0
Intellectual property		16,449		10.0
Non-compete agreement		104		5.0
Tradenames		2,193		10.0

Total intangible assets	$	39,056

The weighted-average amortization period of the acquired intangible assets was 12.6 years.

CardioCel and VascuCel Biologic Patches

On October 11, 2019 (the Closing Date), we entered into an asset purchase agreement (Admedus APA) to acquire the biologic patch business assets and a related technology license from Admedus Ltd (now known as Anteris Technologies Ltd) and various of its subsidiaries (collectively, Admedus). The biologic patch business consists of the CardioCel and VascuCel product lines, which are manufactured in a manner intended to reduce the risk of calcification. The products are sold worldwide. On the same date, the parties entered into a Transition Services Agreement (TSA) under which Admedus will manufacture and supply LeMaitre with inventory for a period of up to three years, unless extended in writing by both parties. In August 2021, the term of this arrangement was extended through July 11, 2023.

Under the Admedus APA we agreed to pay Admedus a total of up to $15.3 million for the purchase of substantially all of its biologic patch business assets, other than specifically identified excluded assets, plus $8.0 million for the technology license. The acquired assets (in combination with the license) included inventory, intellectual property, permits and approvals, data and records, and customer and supplier information, as well as a small amount of machinery and equipment. At closing, $14.2 million of the purchase price was paid to Admedus. Shortly thereafter another $0.3 million was paid in connection with delivery of audited financial statements of the acquired business to LeMaitre. Additional payments of $0.7 million are due within 15 days of the first and third anniversaries of the closing date; the first payment was made in October 2020. Additional contingent consideration was or may be payable as follows:

●

$2.5 million if revenues in the first 12-month period following the Closing Date exceed $20 million, or, $1.2 million if revenues in the first 12-month period following the Closing Date exceed $15 million (this milestone was not met and accordingly no payment was made);

●

$2.5 million if revenues in the second 12-month period following the Closing Date exceed $30 million, or, $1.2 million if revenues in the second 12-month period following the Closing Date exceed $22.5 million (this milestone was not met and accordingly no payment was made);

●

$0.5 million if, by the first anniversary of the Closing Date, Admedus extends the shelf life of the products from 36 months to at least 60 months (this milestone was not met and accordingly no payment was made); and

●

$2.0 million within 15 days following LeMaitre’s receipt of a CE mark under MDR regulations on all acquired products (the Third Holdback Amount).

This contingent consideration of $7.5 million was initially valued in total at $2.0 million and is being re-measured each reporting period until the payment requirement ends, with any adjustments reported in income from operations.

During the quarter ended September 30, 2021, the Company entered into an amendment to the Admedus APA. Under the amendment, the Third Holdback Amount, less a deduction for certain expenses incurred by LeMaitre in order to achieve CE mark certification, will be paid as follows: 75% within 15 days following LeMaitre’s receipt of a CE mark under MDR regulations for CardioCel products, and 25% within 15 days following LeMaitre’s receipt of a CE mark under MDR regulations for VascuCel products. During the quarter ended September 30, 2021 we recorded a reduction to the liability of $0.5 million, with the offset recorded in income from operations, to reflect our estimate of costs to be deducted from the Third Holdback Amount in connection with this amendment.

During the quarter ended September 30, 2020, we recorded a $1.3 million adjustment to goodwill with an offsetting adjustment to deferred income taxes to reflect the difference between book basis and tax basis of the technology license. The following table summarizes the purchase price allocation:

The goodwill results from expected synergies of combining the acquired products and customer information to our existing operations, and is deductible for tax purposes over 15 years.

The following table reflects the allocation of purchase consideration to the acquired intangible assets and related estimated useful lives:

	Allocated
	Fair Value
	(in thousands)
Inventory and other	$	1,343
Deferred tax assets		1,345
Intangible assets		8,725
Goodwill		5,999

Purchase price	$	17,412

The weighted-average amortization period of the acquired intangible assets was 10.4 years.

Tru-Incise Valve Cutter

On July 12, 2019, we entered into an agreement with UreSil, LLC, an Illinois limited liability company, to purchase the remaining assets of their Tru-Incise valve cutter business, including distribution rights in the United States. We also entered into a transition services agreement under which UreSil, LLC would continue to manufacture the acquired products for us for a specified time, until we had transferred the manufacturing process to our Burlington, Massachusetts facilities.

The purchase price for the acquired assets, which included inventory, machinery and equipment, intellectual property, and customer and supplier information, was $8.0 million. Of this amount, $6.8 million was paid at closing, with three follow-on payments $0.4 million each due on the first, second and third anniversaries of the closing date. The deferred amounts totaling $1.2 million were recorded at an acquisition-date fair value of $1.1 million using a discount rate of 4.19% to reflect the time value of money between the acquisition date and the payment due dates. There were no contingencies associated with these holdback payments, although they may be reduced for certain post-closing claims. The first and second payments were made without adjustment in July 2020 and July 2021, respectively.

The following table summarizes the preliminary purchase price allocation:

	Allocated
	Fair Value
	(in thousands)
Inventory	$	276
Equipmentand supplies		70
Intangible assets		4,844
Goodwill		2,748

Purchase price	$	7,938

The goodwill results from expected synergies of combining the acquired products and customer information to our existing operations, and is deductible for tax purposes over 15 years.

The following table reflects the allocation of purchase consideration to the acquired intangible assets and related estimated useful lives:

			Weighted
			*Average*
	Allocated Fair Value		Useful Life (in years)
	(in thousands)
Customer relationships	$	3,945		13.0
Intellectual property		563		7.0
Non-compete agreement		233		5.0
Tradenames		103		7.0

Total intangible assets	$	4,844

The weighted-average amortization period of the acquired intangible assets was 11.8 years.

Note 2 - Acquisitions (Tables)

12 Months Ended

Dec. 31, 2021

Notes Tables

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

	Allocated
	Fair Value
	(in thousands)
Inventory	$	3,859
Accounts receivable		1,789
Equipment and supplies		1,140
Accounts payable and other		(53	)
Intangible assets		39,056
Goodwill		27,115

Purchase price	$	72,906

	Allocated
	Fair Value
	(in thousands)
Inventory and other	$	1,343
Deferred tax assets		1,345
Intangible assets		8,725
Goodwill		5,999

Purchase price	$	17,412

	Allocated
	Fair Value
	(in thousands)
Inventory	$	276
Equipmentand supplies		70
Intangible assets		4,844
Goodwill		2,748

Purchase price	$	7,938

Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]

	Allocated		Estimated
	Fair Value		Useful Life (in years)
	(in thousands)
Customer relationships	$	20,310		15.0
Intellectual property		16,449		10.0
Non-compete agreement		104		5.0
Tradenames		2,193		10.0

Total intangible assets	$	39,056

			Weighted
			*Average*
	Allocated Fair Value		Useful Life (in years)
	(in thousands)
Customer relationships	$	3,945		13.0
Intellectual property		563		7.0
Non-compete agreement		233		5.0
Tradenames		103		7.0

Total intangible assets	$	4,844

Note 5 - Goodwill and Other Intangible Assets - Components of Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Gross carrying value	$ 70,854	$ 74,243
Accumulated amortization	18,144	15,338
Net carrying value	52,710	58,905
Product Technology and Intellectual Property [Member]
Gross carrying value	29,549	29,951
Accumulated amortization	10,473	7,947
Net carrying value	19,076	22,004
Trademarks, Tradenames and Licenses [Member]
Gross carrying value	3,647	4,000
Accumulated amortization	1,139	1,094
Net carrying value	2,508	2,906
Customer Relationships [Member]
Gross carrying value	36,197	38,525
Accumulated amortization	5,674	5,424
Net carrying value	30,523	33,101
Other Intangible Assets [Member]
Gross carrying value	1,461	1,767
Accumulated amortization	858	873
Net carrying value	$ 603	$ 894

Note 9 - Income Taxes (Tables)

12 Months Ended

Dec. 31, 2021

Notes Tables

Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]

	Year ended December 31,
	2021		2020		2019
	(in thousands)

United States	$	34,153	$	25,308	$	17,989
Foreign		134		2,048		3,690

Total	$	34,287	$	27,356	$	21,679

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

	Year ended December 31,
	2021			2020			2019
				(in thousands)
Current:
Federal	$	5,024		$	4,594		$	1,501
State		990			806			304
Foreign		1,287			1,064			1,116

		7,301			6,464			2,921
Deferred:
Federal		63			(397	)		538
State		(9	)		(48	)		144
Foreign		25			117			142

		79			(328	)		824

Provision for income taxes	$	7,380		$	6,136		$	3,745

Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]

	2021			2020			2019
	(in thousands)
Unrecognized tax benefits at the beginning of year	$	820		$	848		$	711
Additions/adjustments for tax positions of current year		-			-			74
Additions/adjustments for tax positions of prior years		(52	)		37			63
Reductions for settlements with taxing authorities.		-			(65	)		-
Reductions for lapses of the applicable statutes of limitations		-			-			-
Unrecognized tax benefits at the end of the year	$	768		$	820		$	848

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	As of December 31,
	2021			2020
	(in thousands)
Deferred tax assets:
Inventory	$	2,231		$	1,629
Net operating loss carryforwards		1,153			1,348
Tax credit carryforwards		1,033			1,019
Capital loss carryforwards		492			521
Reserves and accruals		712			994
Operating lease liabilities		3,562			3,664
Intangible assets		4,426			4,386
Stock options		440			359
Other		140			105

Total deferred tax assets		14,189			14,025

Deferred tax liabilities:
Property and equipment		(1,713	)		(1,831	)
Goodwill		(4,825	)		(4,055	)
Operating lease right-of-use assets		(3,355	)		(3,503	)
Foreign branch deferred offset		(843	)		(954	)
Other		(213	)		(299	)

Total deferred tax liabilities		(10,949	)		(10,642	)

Net deferred tax assets before valuation allowance		3,240			3,383

Valuation allowance		(1,744	)		(1,824	)

Net deferred tax liabiltity	$	1,496		$	1,559

Deferred tax classification
Long-term deferred tax asset	$	1,566		$	1,686
Long-term deferred tax liability		(70	)		(127	)

Net long-term deferred tax asset	$	1,496		$	1,559

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	2021			2020			2019

Federal statutory rate		21.0	%		21.0	%		21.0	%
State tax, net of federal benefit		2.7	%		2.2	%		1.9	%
Effect of foreign taxes		3.7	%		1.1	%		2.1	%
Federal tax on foreign income		0.2	%		0.4	%		0.8	%
Valuation allowance		(0.1	%)		1.4	%		0.6	%
Foreign deferred tax liability offset		(0.1	%)		(0.2	%)		(0.4	%)
Research & development tax credits		(0.4	%)		(0.6	%)		(1.2	%)
Stock options		(3.1	%)		(2.3	%)		(8.8	%)
Uncertain tax positions		0.2	%		0.3	%		1.0	%
Other permanent differences		(2.4	%)		(0.6	%)		0.5	%
Other		(0.2	%)		(0.3	%)		(0.2	%)

Effective tax rate		21.5	%		22.4	%		17.3	%

Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]

	Year ended December 31,
	2021		2020		2019
	(in thousands)
Cash paid for income taxes, net	$	10,147	$	4,470	$	4,817

Note 4 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Gross property and equipment	$ 39,990	$ 35,121
Less accumulated depreciation	(22,931)	(20,085)
Property and equipment, net	17,059	15,036
Computers and Equipment [Member]
Gross property and equipment	5,667	5,046
Machinery and Equipment [Member]
Gross property and equipment	18,439	17,266
Building and Leasehold Improvements [Member]
Gross property and equipment	$ 15,884	$ 12,809

Note 7 - Accrued Expenses and Other Long-term Liabilities

12 Months Ended

Dec. 31, 2021

Notes to Financial Statements

Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block]

7. Accrued Expenses and Other Long-term Liabilities

Accrued expenses consist of the following:

	December 31, 2021		December 31, 2020
	(in thousands)
Compensation and related taxes	$	10,236	$	8,675
Income and other taxes		551		2,394
Professional fees		129		39
Other		5,416		6,417

Total	$	16,332	$	17,525

Other long-term liabilities consist of the following:

	December 31, 2021		December 31, 2020
	(in thousands)
Acquisition-related liabilities	$	1,761	$	3,700
Income taxes		799		813
Other		141		130

Total	$	2,701	$	4,643

Note 10 - Stockholders' Equity

12 Months Ended

Dec. 31, 2021

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

10. Stockholders’ Equity

Authorized Shares

Our certificate of incorporation, as amended and restated from time to time, authorizes the issuance of up to 37,000,000 shares of common stock and up to 3,000,000 shares of undesignated preferred stock.

Under the terms of our certificate of incorporation, our board of directors is authorized to issue shares of the preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. Currently, we have no shares of preferred stock outstanding.

Equity Offering

On July 16, 2021, we closed an offering of 1,000,000 shares of our common stock, $0.01 par value per share, at a price to the public of $54.50 per share, less underwriting discounts. The net proceeds, after deducting the underwriting discounts and other offering expenses, were approximately $51.0 million. We used a portion of the proceeds from the offering to repay our outstanding debt. We plan to use the remaining proceeds for general corporate purposes, including working capital needs and capital expenditures, dividend payments, deferred payments related to prior acquisitions, and the funding of future acquisitions.

On August 4, 2021, the underwriters purchased an additional 150,000 shares pursuant to an option granted to them in connection with the offering described above. The net proceeds to the Company, after deducting underwriting discounts and other offering expenses, were approximately $7.6 million. We plan to use the proceeds for general corporate purposes.

Stock Award Plans

In May 2006 we approved a 2006 Stock Option and Incentive Plan (as subsequently amended, the 2006 Plan), which became effective upon our initial public offering. The 2006 Plan allows for the granting of an aggregate 5,500,000 shares of incentive stock options, non-qualified stock options, stock appreciation rights, RSUs, PSUs, unrestricted stock awards, and deferred stock awards to our officers, employees, directors, and consultants. Incentive stock options are required to be issued at not less than fair market value at the date of the grant and generally vest over four or five years. The term of the options is determined by our Board of Directors but in no event will exceed ten years from date of grant. In connection with the adoption of the 2006 Plan, no further option grants were permitted under any previous stock option plans and any expirations, cancellations, or terminations under the previous plans are available for issuance under the 2006 Plan. We may satisfy awards upon exercise of stock options, RSUs or PSUs with either newly issued shares or treasury shares. The total number of shares currently authorized for the 2006 Plan is 7,118,003 shares, of which 658,935 remain available for grant as of December 31, 2021.

We have computed the fair value of employee stock options granted each year using the following weighted average assumptions:

	2021			2020			2019
Dividend yield		0.91	%		1.02	%		0.96	%
Volatility		46.0	%		47.3	%		42.8	%
Risk-free interest rate		1.1	%		0.3	%		1.7	%
Weighted average expected option term (in years)		4.6			4.9			4.7
Weighted average fair value per share of options granted	$	17.64		$	13.24		$	12.51

A summary of option activity as of December 31, 2021 and for the three years then ended is presented below:

				Weighted		Weighted Average		Aggregate
	*Number*			*Average*		*Remaining*		*Intrinsic*
	*of Shares*			*Exercise Price*		*Contractual Term*		*Value*
						(in years)		(in thousands)

Balance outstanding at December 31, 2018		1,462,575		$	16.41		4.54	$	12,214

Granted		195,379		$	35.53
Exercised		(509,693	)	$	9.53			$	11,488
Canceled / Expired		(101,167	)	$	17.90

Balance outstanding at December 31, 2019		1,047,094		$	28.22		4.31	$	13,367

Granted		222,110		$	36.67
Exercised		(331,958	)	$	17.99			$	5,413
Canceled / Expired		(5,406	)	$	27.49

Balance outstanding at December 31, 2020		931,840		$	28.22		4.49	$	11,442

Granted		151,161		$	48.60
Exercised		(217,121	)	$	20.95			$	6,975
Canceled / Expired		(19,126	)	$	23.18
Balance outstanding at December 31, 2021		846,754		$	33.83		4.50	$	13,888

Exercisable at:
December 31, 2019		309,501		$	19.64		3.50	$	5,047
December 31, 2020		274,411		$	23.08		3.50	$	4,781
December 31, 2021		301,692		$	27.40		3.30	$	6,886

Expected to vest at:
December 31, 2019		737,593		$	24.68		4.65
December 31, 2020		657,429		$	30.37		4.93
December 31, 2021		545,062		$	37.38		5.16

Cash received from stock options exercised during the years ended December 31, 2021, 2020 and 2019 was $4.5 million, $6.0 million and $4.9 million, respectively.

Restricted Stock Units and Performance-based Restricted Stock Units

The fair value of restricted stock unit awards with time-based vesting is based on the intrinsic value of the awards at the date of grant.

We also issue restricted stock unit awards with vesting based on performance conditions. Performance-based restricted stock units awarded in 2021 will vest based on our achievement of operating income relative to our target operating income. For restricted stock unit awards that include vesting based on performance conditions, the fair values are based on the intrinsic values of the awards at the date of grant.

A summary of our restricted stock unit activity as of December 31, 2021 and for the three years then ended is presented below:

				Weighted
				Average
	*Number*			*Grant Date*
	*of Shares*			*Fair Value*

Balance outstanding at December 31, 2018		217,895		$	21.21

Granted		56,567		$	35.41
Vested		(61,058	)	$	18.46
Canceled		(24,723	)	$	22.19

Balance outstanding at December 31, 2019		188,681		$	26.14

Granted		46,146		$	36.86
Vested		(50,669	)	$	22.76
Canceled		(37,143	)	$	27.88

Balance outstanding at December 31, 2020		147,015		$	30.24

Granted		48,298		$	48.65
Vested		(51,414	)	$	26.32
Canceled		(10,068	)	$	30.70

Balance outstanding at December 31, 2021		133,831		$	38.26

A summary of our performance-based restricted stock unit activity as of December 31, 2021 and for the three years then ended is presented below:

			Weighted
			Average
	*Number*		*Grant Date*
	*of Shares*		*Fair Value*

Balance outstanding at December 31, 2020		-	$	-

Granted		31,181	$	48.60
Vested		-	$	-
Canceled		-	$	-

Balance outstanding at December 31, 2021		31,181	$	48.60

The number of RSUs vested includes the shares that we withheld on behalf of employees to satisfy minimum statutory tax withholding requirements. The fair values of the RSUs that vested during 2021, 2020 and 2019 were $2.5 million, $1.8 million, and $2.1 million, respectively.

We repurchase shares of our common stock in order to cover any minimum tax withholding liability associated with RSU vestings. A summary of our repurchases is as follows:

	2021		2020		2019

Shares of common stock repurchased for net settlement of equity awards		16,333		16,537		20,524
Average per share repurchase price	$	49.10	$	34.47	$	33.28
Aggregage purchase price (in thousands)	$	802	$	570	$	683

Stock-based Compensation

The components of stock-based compensation expense included in the consolidated statements of operations are as follows:

	2021		2020		2019
	(in thousands)
Stock option awards	$	2,199	$	1,938	$	1,580
Restricted stock units		1,247		1,084		1,062
Performance-based restricted stock units		33		-		-

Total stock-based compensation	$	3,479	$	3,022	$	2,642

Stock-based compensation is included in our statements of operations as follows:

	2021		2020		2019
	(in thousands)
Cost of sales	$	407	$	333	$	310
Sales and marketing		527		516		544
General and administrative		2,185		1,883		1,509
Research and development		360		290		279

Total stock-based compensation	$	3,479	$	3,022	$	2,642

We expect to record the unamortized portion of share-based compensation expense of $13.1 million for existing stock options and RSUs outstanding at December 31, 2021, over a weighted-average period of 3.3 years.

Stock Repurchase Plans

On February 22, 2022, our Board of Directors authorized the repurchase of up to $20.0 million of the Company’s common stock through transactions on the open market, in privately negotiated purchases or otherwise until February 22, 2023. The repurchase program may be suspended or discontinued at any time. To date we have not made any repurchases under this program.

Dividends

In February 2011, our Board of Directors approved a policy for the payment of quarterly cash dividends on our common stock. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by our Board of Directors on a quarterly basis. The dividend activity for the periods presented is as follows:

Record Date	Payment Date	Per Share Amount		Dividend Payment
				(in thousands)
Fiscal Year 2021
March 9, 2021	March 25, 2021	$	0.110	$	2,262
May 19, 2021	June 3, 2021	$	0.110	$	2,267
August 26, 2021	September 9, 2021	$	0.110	$	2,401
November 19, 2021	December 2, 2021	$	0.110	$	2,405

Fiscal Year 2020
March 3, 2020	March 19, 2020	$	0.095	$	1,917
May 20, 2020	June 4, 2020	$	0.095	$	1,917
August 27, 2020	September 10, 2020	$	0.095	$	1,925
November 19, 2020	December 3, 2020	$	0.095	$	1,936

On February 22, 2022, our Board of Directors approved a quarterly cash dividend on our common stock of $0.125 per share payable on March 24, 2022, to stockholders of record at the close of business on March 8, 2022, which will total approximately $2.7 million.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Note 5 - Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2021

Notes Tables

Schedule of Goodwill [Table Text Block]

	As of December 31,
	2021		2020

Balance at beginning of year	$	65,945	$	39,951
Additions for acquisitions		-		27,115
Purchase accounting adjustments		-		(1,345	)
Effects of currency exchange		-		224

Balance at end of year	$	65,945	$	65,945

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	December 31, 2021						December 31, 2020
	Gross				Net		Gross				Net
	Carrying		Accumulated		Carrying		Carrying		Accumulated		Carrying
	Value		Amortization		Value		Value		Amortization		Value
	(in thousands)
Product technology and intellectual property	$	29,549	$	10,473	$	19,076	$	29,951	$	7,947	$	22,004
Trademarks, tradenames and licenses		3,647		1,139		2,508		4,000		1,094		2,906
Customer relationships		36,197		5,674		30,523		38,525		5,424		33,101
Other intangible assets		1,461		858		603		1,767		873		894

Total identifiable intangible assets	$	70,854	$	18,144	$	52,710	$	74,243	$	15,338	$	58,905

Finite-lived Intangible Assets Amortization Expense [Table Text Block]

	Year ended December 31,
	2021		2020		2019
			(in thousands)

Amortization expense	$	6,195	$	5,043	$	2,437

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

	Year ended December 31,
	2022		2023		2024		2025		2026
	(in thousands)

Amortization expense	$	6,016	$	5,884	$	5,702	$	5,464	$	4,997

Note 5 - Goodwill and Other Intangible Assets

12 Months Ended

Dec. 31, 2021

Notes to Financial Statements

Goodwill and Intangible Assets Disclosure [Text Block]

5. Goodwill and Other Intangibles

Goodwill consists of the following:

	As of December 31,
	2021		2020

Balance at beginning of year	$	65,945	$	39,951
Additions for acquisitions		-		27,115
Purchase accounting adjustments		-		(1,345	)
Effects of currency exchange		-		224

Balance at end of year	$	65,945	$	65,945

During 2020, we recorded a $1.3 million adjustment to goodwill with an offsetting adjustment to deferred income taxes to reflect the difference between book basis and tax basis of the technology license acquired under the CardioCel APA.

Other intangibles consist of the following:

	December 31, 2021						December 31, 2020
	Gross				Net		Gross				Net
	Carrying		Accumulated		Carrying		Carrying		Accumulated		Carrying
	Value		Amortization		Value		Value		Amortization		Value
	(in thousands)
Product technology and intellectual property	$	29,549	$	10,473	$	19,076	$	29,951	$	7,947	$	22,004
Trademarks, tradenames and licenses		3,647		1,139		2,508		4,000		1,094		2,906
Customer relationships		36,197		5,674		30,523		38,525		5,424		33,101
Other intangible assets		1,461		858		603		1,767		873		894

Total identifiable intangible assets	$	70,854	$	18,144	$	52,710	$	74,243	$	15,338	$	58,905

These assets are being amortized over useful lives ranging from 2 to 16 years. The weighted-average amortization period for these intangibles as of December 31, 2021, is 11.0 years. Amortization expense is included in general and administrative expense and is as follows:

	Year ended December 31,
	2021		2020		2019
			(in thousands)

Amortization expense	$	6,195	$	5,043	$	2,437

During the years ended December 31, 2021 and 2019, we wrote off fully amortized intangible assets with gross values of $3.4 million and $4.5 million, respectively. Estimated amortization expense for each of the next five fiscal years, based upon the intangible assets at December 31, 2021, is as follows:

	Year ended December 31,
	2022		2023		2024		2025		2026
	(in thousands)

Amortization expense	$	6,016	$	5,884	$	5,702	$	5,464	$	4,997

Note 6 - Revolving Line of Credit and Long-term Debt

12 Months Ended

Dec. 31, 2021

Notes to Financial Statements

Debt Disclosure [Text Block]

6. Revolving Line of Credit and Long-term Debt

In connection with the acquisition of the Artegraft biologic graft business, we incurred debt in the amount of $65 million under a senior secured credit facility with a group of banks. This credit arrangement included a $25 million revolving credit line that was fully drawn at inception, as well as a $40 million five-year term loan. During the year ended December 31, 2020, we made scheduled principal payments on the term loan of $1.0 million and repaid the revolving line of credit in full. During the year ended December 31, 2021, we made scheduled principal payments on the term loan of $1.0 million, repaid the loan in full, and terminated the credit agreement in accordance with its terms.

Under the terms of the agreement, the loans bore interest at a rate per annum of, at our option, either (i) the Base Rate plus an applicable margin of from 1.25% to 1.75% depending on our consolidated leverage ratio, or (ii) the Eurodollar Rate plus an applicable margin of from 2.25% to 2.75% depending on our consolidated leverage ratio. Base Rate is defined in the credit agreement as a fluctuating rate per annum of the Federal Funds rate plus 0.5% or the prime rate of interest established from time to time by KeyBank National Association. Cash paid for interest during both of the years ended December 31, 2021 and 2020 was $0.9 million.

We incurred debt issuance costs in connection with this credit arrangement of approximately $1.8 million. These costs were allocated between the revolving line of credit and the term loans, with the portion related to the revolving line of credit of $0.7 million recorded in other assets on our balance sheet, and the portion allocated to the term loan recorded as a deduction from the amount of the debt. All of these transaction costs were being amortized into interest expense on a straight-line basis as the result would not be materially different from using the interest method, over the five-year term of the arrangement. This resulted in an effective interest rate of approximately 4.2%.

During the three months ended September 30, 2021, in connection with prepaying the term loan in full, we expensed the remaining unamortized transaction costs allocated to the term loan of $0.6 million. The term of the revolving line of credit was five years, with all outstanding amounts due on June 22, 2025. In November 2021 we terminated the credit agreement, including the revolving line of credit, as allowed for in the original agreement, and expensed the remaining unamortized transaction costs allocated to the revolving line of credit of $0.5 million.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Note 10 - Stockholders' Equity - Summary of PBS Activity (Details) - Performance Shares [Member]

12 Months Ended

Dec. 31, 2021

$ / shares

Outstanding (in shares) | shares

Outstanding, weighted average grant date fair value (in dollars per share) | $ / shares

$ 0

Granted (in shares) | shares

31,181

Granted, weighted average grant date fair value (in dollars per share) | $ / shares

$ 48.60

Vested (in shares) | shares

^[1]

Vested, weighted average grant date fair value (in dollars per share) | $ / shares

$ 0

^[1]

Canceled (in shares) | shares

Canceled, weighted average grant date fair value (in dollars per share) | $ / shares

$ 0

Outstanding (in shares) | shares

31,181

Outstanding, weighted average grant date fair value (in dollars per share) | $ / shares

$ 48.60

[1]	The number of RSUs vested includes the shares that we withheld on behalf of employees to satisfy minimum statutory tax withholding requirements. The fair values of the RSUs that vested during 2020, 2019 and 2018 were $1.8 million, $2.1 million, and $1.9 million, respectively.

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Assets
Cash and cash equivalents	$ 13,855	$ 26,764
Short-term marketable securities	56,104	214
Accounts receivable, net of allowances of $679 at December 31, 2021, and $623 at December 31, 2020	19,631	19,552
Inventory and other deferred costs	46,104	45,115
Prepaid expenses and other current assets	4,189	2,618
Total current assets	139,883	94,263
Property and equipment, net	17,059	15,036
Right-of-use leased assets	15,071	16,066
Goodwill	65,945	65,945
Other intangibles, net	52,710	58,905
Deferred tax assets	1,566	1,686
Other assets	568	909
Total assets	292,802	252,810
Liabilities and stockholders’ equity
Current portion of long-term debt	0	2,500
Accounts payable	2,340	2,394
Accrued expenses	16,332	17,525
Acquisition-related obligations	1,271	772
Lease liabilities - short-term	1,870	1,954
Total current liabilities	21,813	25,145
Long-term debt, net	0	35,532
Lease liabilities - long-term	14,067	14,791
Deferred tax liabilities	70	127
Other long-term liabilities	2,701	4,643
Total liabilities	38,651	80,238
Stockholders’ equity:
Preferred stock, $0.01 par value; authorized 3,000,000 shares; none outstanding	0	0
Common stock, $0.01 par value; authorized 37,000,000 shares; issued 23,477,784 shares at December 31, 2021, and 22,061,554 shares at December 31, 2020	235	221
Additional paid-in capital	181,630	114,924
Retained earnings	88,125	70,554
Accumulated other comprehensive loss	(3,435)	(1,525)
Treasury stock, at cost; 1,554,905 shares at December 31, 2021 and 1,538,572 shares at December 31, 2020	(12,404)	(11,602)
Total stockholders’ equity	254,151	172,572
Total liabilities and stockholders’ equity	$ 292,802	$ 252,810

Note 10 - Stockholders' Equity - Summary of Repurchases (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Shares of common stock repurchased for net settlement of equity awards (in shares)	16,333	16,537	20,524
Restricted Stock Units (RSUs) [Member]
Average per share repurchase price (in dollars per share)	$ 49.10	$ 34.47	$ 33.28
Aggregage purchase price (in thousands)	$ 802	$ 570	$ 683

Note 5 - Goodwill and Other Intangibles - Schedule of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Balance at beginning of year	$ 65,945	$ 39,951
Additions for acquisitions	0	27,115
Purchase accounting adjustments	0	(1,345)
Effects of currency exchange	0	224
Balance at end of year	$ 65,945	$ 65,945

Note 5 - Goodwill and Other Intangible Assets - Amortization Expense Included in General and Administrative Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Amortization expense	$ 6,195	$ 5,043	$ 2,437

Note 8 - Commitments and Contingencies - Additional Lease Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating lease cost	$ 2,275	$ 1,912
Short-term lease cost	458	192
Total lease cost	2,733	2,104
Cash paid for amounts included in the measurement of operating lease liabilities	2,859	2,404
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 1,277	$ 2,770
Weighted average remaining lease term - operating leases (in years) (Year)	7 years 3 months 18 days	7 years 9 months 18 days
Weighted average discount rate - operating leases	4.86%	5.02%

Note 9 - Income Taxes - The Provision (Benefit) for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current:
Federal	$ 5,024	$ 4,594	$ 1,501
State	990	806	304
Foreign	1,287	1,064	1,116
Current Income Tax Expense (Benefit), Total	7,301	6,464	2,921
Deferred:
Federal	63	(397)	538
State	(9)	(48)	144
Foreign	25	117	142
Deferred Income Tax Expense (Benefit), Total	79	(328)	824
Provision for income taxes	$ 7,380	$ 6,136	$ 3,745

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accounts receivable, allowances	$ 679	$ 623
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	3,000,000	3,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	37,000,000	37,000,000
Common stock, shares issued (in shares)	23,477,784	22,061,554
Treasury stock, at cost (in shares)	1,554,905	1,538,572

Note 10 - Stockholders' Equity - Summary of Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Outstanding (in shares)	931,840	1,047,094	1,462,575
Outstanding, weighted average exercise price (in dollars per share)	$ 28.22	$ 28.22	$ 16.41
Outstanding, weighted average contractual term (Year)	4 years 6 months	4 years 5 months 26 days	4 years 3 months 21 days	4 years 6 months 14 days
Outstanding, aggregate intrinsic value	$ 13,888	$ 11,442	$ 13,367	$ 12,214
Granted (in shares)	151,161	222,110	195,379
Granted, weighted average exercise price (in dollars per share)	$ 48.60	$ 36.67	$ 35.53
Exercised (in shares)	(217,121)	(331,958)	(509,693)
Exercised, weighted average exercise price (in dollars per share)	$ 20.95	$ 17.99	$ 9.53
Exercised, aggregate intrinsic value	$ 6,975	$ 5,413	$ 11,488
Canceled / Expired (in shares)	(19,126)	(5,406)	(101,167)
Canceled / Expired, weighted average exercise price (in dollars per share)	$ 23.18	$ 27.49	$ 17.90
Outstanding (in shares)	846,754	931,840	1,047,094	1,462,575
Outstanding, weighted average exercise price (in dollars per share)	$ 33.83	$ 28.22	$ 28.22	$ 16.41
Exercisable (in shares)	301,692	274,411	309,501
Exercisable, weighted average exercise price (in dollars per share)	$ 27.40	$ 23.08	$ 19.64
Exercisable, weighted average contractual term (Year)	3 years 3 months 18 days	3 years 6 months	3 years 6 months
Exercisable, aggregate intrinsic value	$ 6,886	$ 4,781	$ 5,047
Expected to vest (in shares)	545,062	657,429	737,593
Expected to vest, weighted average exercise price (in dollars per share)	$ 37.38	$ 30.37	$ 24.68
Expected to vest, weighted average contractual term (Year)	5 years 1 month 28 days	4 years 11 months 4 days	4 years 7 months 24 days

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Net sales	$ 154,424	$ 129,366	$ 117,232
Cost of sales	53,042	44,748	37,379
Gross profit	101,382	84,618	79,853
Sales and marketing	27,655	23,700	30,339
General and administrative	25,501	22,501	19,055
Research and development	11,801	10,099	9,276
Gains on sale of building, acquisitions and divestitures	0	(470)	0
Total operating expenses	64,957	55,830	58,670
Income from operations	36,425	28,788	21,183
Other income (expense):
Interest income	197	207	698
Interest expense	(2,219)	(1,310)	0
Foreign currency loss	(116)	(329)	(202)
Income before income taxes	34,287	27,356	21,679
Provision for income taxes	7,380	6,136	3,745
Net income	$ 26,907	$ 21,220	$ 17,934
Earnings per share of common stock:
Basic (in dollars per share)	$ 1.27	$ 1.05	$ 0.91
Diluted (in dollars per share)	$ 1.25	$ 1.04	$ 0.88
Weighted-average shares outstanding:
Basic (in shares)	21,157	20,246	19,813
Diluted (in shares)	21,475	20,479	20,326
Cash dividends declared per common share (in dollars per share)	$ 0.44	$ 0.38	$ 0.34

Note 11 - Profit-sharing Plan

12 Months Ended

Dec. 31, 2021

Notes to Financial Statements

Compensation and Employee Benefit Plans [Text Block]

11. Profit-Sharing Plan

We offer a 401(k) profit-sharing plan (the Plan) covering eligible U.S. employees to make tax-deferred contributions, a portion of which are matched by us. We may also make discretionary profit sharing contributions to the Plan in an amount determined by our Board of Directors. Our contributions vest ratably over six years of employment and amounted to approximately $0.5 million, $0.3 million and $0.4 million for 2021, 2020 and 2019, respectively. A similar plan is offered to our Canadian employees.

Note 1 - Significant Accounting Policies and Related Matters - Computation of Basic and Diluted Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Basic:
Net income available for common stockholders	$ 6,175	$ 6,504	$ 8,299	$ 5,929	$ 7,033	$ 7,513	$ 3,500	$ 3,174	$ 26,907	$ 21,220	$ 17,934
Weighted average shares outstanding (in shares)									21,157	20,246	19,813
Basic earnings per share (in dollars per share)	$ 0.28	$ 0.30	$ 0.40	$ 0.29	$ 0.35	$ 0.37	$ 0.17	$ 0.16	$ 1.27	$ 1.05	$ 0.91
Common stock equivalents, if dilutive (in shares)									318	233	513
Shares used in computing diluted earnings per common share (in shares)									21,475	20,479	20,326
Diluted earnings per share (in dollars per share)	$ 0.28	$ 0.30	$ 0.40	$ 0.28	$ 0.34	$ 0.37	$ 0.17	$ 0.16	$ 1.25	$ 1.04	$ 0.88
Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive (in shares)									10	483	468

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Note 13 - Fair Value Measurements

12 Months Ended

Dec. 31, 2021

Notes to Financial Statements

Fair Value Disclosures [Text Block]

13. Fair Value Measurements

The fair value accounting guidance requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

•

Level 1 — Quoted prices in active markets for identical assets or liabilities.

•

Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

•

Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

Level 1 assets being measured at fair value on a recurring basis as of December 31, 2021 included our short-term investment mutual fund account.

We had no Level 2 assets being measured at fair value on a recurring basis as of December 31, 2021.

As discussed in Notes 1 and 2, several of our acquisition-related assets and liabilities have been measured using Level 3 techniques. During 2020 we recorded a contingent liability associated with our acquisition of the bovine carotid graft business from Artegraft. As discussed more fully in Note 2, the agreement requires us to make potential additional payments to Artegraft of up to $17.5 million depending on the achievement of certain unit sales milestones during the first three calendar years following the acquisition. We recorded this liability at a fair value of $0.4 million to reflect management’s estimate of the likelihood of achieving these targets at the time of the Closing, as well as the time value of money until payment. This amount is being remeasured each quarter during the earn-out period, with any adjustments recorded in income from operations. During the quarter ended December 31, 2021 we recorded a reduction to the liability to reflect a change in our estimate of the likelihood of achieving the unit sales milestones.

During 2019, we recorded contingent liabilities associated with our acquisition of the Admedus biologic patch business. The agreement includes the potential for us to pay up to $7.8 million of additional consideration beyond payments made to date, with $0.3 million contingent upon the delivery of audited financial statement of the acquired business to us; $2.0 million contingent on LeMaitre’s success in obtaining CE marks under MDR regulations on the acquired products, $0.5 million contingent upon Admedus’ success in extending the shelf life of the acquired products as specified in the agreement, and another $5.0 million contingent on the achievement of specified levels of revenues in the first 12 and 24 months following the acquisition date. This additional contingent consideration was initially valued in total at $2.3 million and is being re-measured each reporting period until the payment requirement ends, with any adjustments reported in income from operations. The contingent payment related to the delivery of audited financial statements of the business was paid in November 2019 upon satisfaction of the deliverable. The contingent payments related to Admedus’ extending the shelf life of the acquired products and achieving the revenue targets during the first 12 and 24 month periods following the acquisition were not met, and the portion of the liabilities related to these items was adjusted through income from operations. The agreement was amended in August 2021 such that the contingent payment of $2.0 million potentially due upon LeMaitre Vascular’s success in obtaining CE marks under MDR regulations on the acquired products may be reduced for certain costs incurred by LeMaitre in achieving the CE marks. During the quarter ended September 30, 2021 we recorded a reduction to the liability of $0.5 million, with the offset recorded in income from operations, to reflect our estimate of costs to be deducted from the contingent payment in connection with this amendment.

The following table provides a rollforward of the fair value of these liabilities, as determined by Level 3 unobservable inputs including management’s forecast of future revenues for the acquired businesses, as well as, management’s estimates of the likelihood of achieving the other specified criteria:

	Year ended December 31,
	2021			2020		2019
	(in thousands)
Beginning balance	$	2,240		$	1,764	$	72
Additions		-			406		1,989
Payments		-			-		(309	)
Change in fair value included in earnings		(748	)		70		12

Ending balance	$	1,492		$	2,240	$	1,764

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Note 12 - Segment and Enterprise-wide Disclosures (Tables)

12 Months Ended

Dec. 31, 2021

Notes Tables

Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]

	Year ended December 31,
	2021		2020		2019
	(in thousands)

United States	$	93,866	$	75,222	$	63,130
Germany		12,968		12,365		12,400
Other countries		47,590		41,779		41,702

Net sales	$	154,424	$	129,366	$	117,232

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]

	As of December 31,
	2021		2020
	(in thousands)

United States	$	28,402	$	27,660
France		1,038		1,140
Germany		781		1,138
Other countries		1,909		1,164

Total long-term assets	$	32,130	$	31,102

Note 1 - Significant Accounting Policies and Related Matters - Summary of Advertising Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Advertising expense	$ 236	$ 216	$ 286

Note 10 - Stockholders' Equity - Weighted Average Assumptions (Details) - Share-based Payment Arrangement, Option [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Dividend yield	0.91%	1.02%	0.96%
Volatility	46.00%	47.30%	42.80%
Risk-free interest rate	1.10%	0.30%	1.70%
Weighted average expected option term (Year)	4 years 7 months 6 days	4 years 10 months 24 days	4 years 8 months 12 days
Weighted average fair value per share of options granted (in dollars per share)	$ 17.64	$ 13.24	$ 12.51

Note 10 - Stockholders' Equity - Dividend Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Per share amount (in dollars per share)	$ 0.44	$ 0.38	$ 0.34
Quarterly Dividends 1 [Member]
Payment date	Mar. 25, 2021	Mar. 19, 2020
Per share amount (in dollars per share)	$ 0.110	$ 0.095
Dividend payment	$ 2,262	$ 1,917
Quarterly Dividends 2 [Member]
Payment date	Jun. 03, 2021	Jun. 04, 2020
Per share amount (in dollars per share)	$ 0.110	$ 0.095
Dividend payment	$ 2,267	$ 1,917
Quarterly Dividends 3 [Member]
Payment date	Sep. 09, 2021	Sep. 10, 2020
Per share amount (in dollars per share)	$ 0.110	$ 0.095
Dividend payment	$ 2,401	$ 1,925
Quarterly Dividends 4 [Member]
Payment date	Dec. 02, 2021	Dec. 03, 2020
Per share amount (in dollars per share)	$ 0.110	$ 0.095
Dividend payment	$ 2,405	$ 1,936

Note 2 - Acquisitions (Details Textual)				3 Months Ended		12 Months Ended
Note 2 - Acquisitions (Details Textual)	Jun. 22, 2020 USD ($)	Oct. 11, 2019 USD ($)	Jul. 12, 2019 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Mar. 31, 2021 USD ($)
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability						$ (674,000)	$ 182,000	$ 171,000
Goodwill, Purchase Accounting Adjustments						0	(1,345,000)
Artegraft Inc [Member]
Payments to Acquire Businesses, Gross	$ 72,500,000
Escrow Deposit Disbursements Related to Property Acquisition	$ 7,500,000
Business Combination, Contingent Consideration, Liability, Total						$ 400,000
Business Acquisition, Purchase Price Allocation, Goodwill Expected Tax Deductible, Period (Year)	15 years
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (Year)	12 years 7 months 6 days
Artegraft Inc [Member] \| First Earn-out [Member]
Business Combination, Contingent Consideration, Liability, Total	$ 5,800,000
Business Combination, Contingent Consideration, Unit Sales	20,000
Artegraft Inc [Member] \| Second Earn-out [Member]
Business Combination, Contingent Consideration, Liability, Total	$ 5,800,000
Business Combination, Contingent Consideration, Unit Sales	24,000
Artegraft Inc [Member] \| Third Earn-out [Member]
Business Combination, Contingent Consideration, Liability, Total	$ 5,800,000
Business Combination, Contingent Consideration, Unit Sales	28,800
Artegraft Inc [Member] \| Catch-Up Payment [Member]
Business Combination, Contingent Consideration, Liability, Total	$ 400,000
Business Combination, Contingent Consideration, Minimum Unit Sales in Three Years	58,240
Business Combination, Contingent Consideration, Minimum Unit Sales in Three Years, Percent of Combined Individual Year Targets	80.00%
Business Combination, Contingent Consideration, Before Multiplied by Fraction	$ 17,500,000
Business Combination, Contingent Consideration, Denominator, Less Amount Paid	72,800
Artegraft Inc [Member] \| Maximum [Member]
Business Combination, Consideration Transferred, Total	$ 90,000,000.0
CardioCel and VascuCel Biologic Patches [Member]
Payments to Acquire Businesses, Gross		$ 14,200,000
Business Combination, Contingent Consideration, Liability, Total		7,500,000							$ 2,000,000.0
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (Year)						10 years 4 months 24 days
Goodwill, Purchase Accounting Adjustments					$ (1,300,000)		$ 1,300,000
CardioCel and VascuCel Biologic Patches [Member] \| Technology Licenses [Member]
Business Combination, Consideration Transferred, Total		8,000,000.0
CardioCel and VascuCel Biologic Patches [Member] \| Achieving Audited Financial Statements of Acquired Business [Member]
Payments to Acquire Businesses, Gross		300,000
CardioCel and VascuCel Biologic Patches [Member] \| First Holdback [Member]
Business Combination, Contingent Consideration, Liability, Total		700,000
CardioCel and VascuCel Biologic Patches [Member] \| Revenues Exceeding Twenty Million in the First Twelve Month Period After Closing Date [Member]
Business Combination, Contingent Consideration, Liability, Total		2,500,000
CardioCel and VascuCel Biologic Patches [Member] \| Revenues Exceeding Fifteen Million in the First Twelve Month Period After Closing Date [Member]
Business Combination, Contingent Consideration, Liability, Total		1,200,000
CardioCel and VascuCel Biologic Patches [Member] \| Revenues Exceeding Thirty Million in the Second Twelve Month Period After Closing Date [Member]
Business Combination, Contingent Consideration, Liability, Total		2,500,000
CardioCel and VascuCel Biologic Patches [Member] \| Revenues Exceeding Twenty-Two and a Half Million in the First Twelve Month Period After Closing Date [Member]
Business Combination, Contingent Consideration, Liability, Total		1,200,000
CardioCel and VascuCel Biologic Patches [Member] \| Extension of Product Shelf Life from 36 Months to 60 Months in the First Anniversary of Closing Date [Member]
Business Combination, Contingent Consideration, Liability, Total		500,000
CardioCel and VascuCel Biologic Patches [Member] \| Third Holdback [Member]
Business Combination, Contingent Consideration, Liability, Total		2,000,000.0
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability				$ (500,000)
CardioCel and VascuCel Biologic Patches [Member] \| Third Holdback [Member] \| CardioCel Product [Member]
Business Combination, Contingent Consideration, Liability, Percent				75.00%
CardioCel and VascuCel Biologic Patches [Member] \| Third Holdback [Member] \| VascuCel Product [Member]
Business Combination, Contingent Consideration, Liability, Percent				25.00%
CardioCel and VascuCel Biologic Patches [Member] \| Maximum [Member] \| Biological Patch Business Assets [Member]
Business Combination, Consideration Transferred, Total		$ 15,300,000
Tru-Incise Valve Cutter [Member]
Business Combination, Consideration Transferred, Total			$ 8,000,000.0
Payments to Acquire Businesses, Gross			$ 6,800,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (Year)			11 years 9 months 18 days
Business Combination, Deferred Purchase Consideration, Installment Payment			$ 400,000
Business Combination, Deferred Purchase Consideration			1,200,000
Acquisition Date Fair Value			$ 1,100,000
Business Combination ,Fair Value Inputs, Discount Rate			4.19%

Note 10 - Stockholders' Equity - Summary of RSU Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares

12 Months Ended

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

Outstanding (in shares)

147,015

188,681

217,895

Outstanding, weighted average grant date fair value (in dollars per share)

$ 30.24

$ 26.14

$ 21.21

Granted (in shares)

48,298

46,146

56,567

Granted, weighted average grant date fair value (in dollars per share)

$ 48.65

$ 36.86

$ 35.41

Vested (in shares)

(51,414)

(50,669)

(61,058)

^[1]

Vested, weighted average grant date fair value (in dollars per share)

$ 26.32

$ 22.76

$ 18.46

^[1]

Canceled (in shares)

(10,068)

(37,143)

(24,723)

Canceled, weighted average grant date fair value (in dollars per share)

$ 30.70

$ 27.88

$ 22.19

Outstanding (in shares)

133,831

147,015

188,681

Outstanding, weighted average grant date fair value (in dollars per share)

$ 38.26

$ 30.24

$ 26.14

[1]	The number of RSUs vested includes the shares that we withheld on behalf of employees to satisfy minimum statutory tax withholding requirements. The fair values of the RSUs that vested during 2020, 2019 and 2018 were $1.8 million, $2.1 million, and $1.9 million, respectively.

Note 4 - Property and Equipment (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Impairment, Long-Lived Asset, Held-for-Use, Total	$ 0.1	$ 0.6	$ 0.5

Note 14 - Accumulated Other Comprehensive Income (Loss)

12 Months Ended

Dec. 31, 2021

Notes to Financial Statements

Comprehensive Income (Loss) Note [Text Block]

14. Accumulated Other Comprehensive Income (Loss)

	Year ended December 31,
	2021			2020			2019
	(in thousands)
Beginning balance	$	(1,525	)	$	(4,007	)	$	(3,900	)

Other comprehensive income (loss) before reclassifications		(1,910	)		2,482			(107	)
Amounts reclassified from accumulated other comprehensive loss		-			-			-

Ending Balance	$	(3,435	)	$	(1,525	)	$	(4,007	)

Changes to our accumulated other comprehensive loss consisted primarily of foreign currency translation for the years ended December 31, 2021, 2020 and 2019.

Note 6 - Revolving Line of Credit and Long-term Debt (Details Textual) - Senior Secured Credit Facility [Member] - USD ($) $ in Millions		6 Months Ended	12 Months Ended
	Jun. 22, 2020	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Nov. 30, 2021
Debt Instrument, Face Amount	$ 65.0
Debt Issuance Costs, Net, Total	1.8
Debt Instrument, Interest Rate, Effective Percentage		4.20%	4.20%
Term Loan [Member]
Debt Instrument, Face Amount	$ 40.0
Debt Instrument, Term (Year)	5 years
Repayments of Long-term Debt, Total			$ 1.0	$ 1.0
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total			$ 0.9
Amortization of Debt Issuance Costs		$ 0.6
Term Loan [Member] \| Base Rate [Member] \| Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate	1.25%
Term Loan [Member] \| Base Rate [Member] \| Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate	1.75%
Term Loan [Member] \| Eurodollar [Member] \| Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate	2.25%
Term Loan [Member] \| Eurodollar [Member] \| Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate	2.75%
Term Loan [Member] \| Fed Funds Effective Rate Overnight Index Swap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	0.50%
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total				$ 0.9
Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 25.0
Debt Instrument, Term (Year)	5 years
Unamortized Debt Issuance Expense					$ 0.5
Revolving Credit Facility [Member] \| Other Assets [Member]
Debt Issuance Costs, Line of Credit Arrangements, Net, Total	$ 0.7

Note 15 - Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2021

Notes to Financial Statements

Quarterly Financial Information [Text Block]

15. Quarterly Financial Data (unaudited)

	Three months ended
2021	March 31		June 30		September 30		December 31
	(in thousands, except per share data)
Total net sales	$	35,883	$	40,670	$	38,368	$	39,503
Gross profit		23,799		26,761		24,866		25,956
Income from operations		7,945		11,106		9,073		8,301
Net income		5,929		8,299		6,504		6,175
Earnings per share
Basic	$	0.29	$	0.40	$	0.30	$	0.28
Diluted	$	0.28	$	0.40	$	0.30	$	0.28

	Three months ended
2020	March 31		June 30		September 30		December 31
	(in thousands, except per share data)
Total net sales	$	30,551	$	24,851	$	36,416	$	37,548
Gross profit		20,483		17,029		22,704		24,402
Income from operations		4,353		4,872		10,018		9,545
Net income		3,174		3,500		7,513		7,033
Earnings per share
Basic	$	0.16	$	0.17	$	0.37	$	0.35
Diluted	$	0.16	$	0.17	$	0.37	$	0.34

Note 2 - Acquisitions - Acquired Intangible Assets and Related Estimated Useful Lives (Details) - USD ($) $ in Thousands	Jun. 22, 2020	Sep. 20, 2018
Artegraft Inc [Member]
Allocated Fair Value	$ 39,056
Weighted Average Useful Life (Year)	12 years 7 months 6 days
Artegraft Inc [Member] \| Customer Relationships [Member]
Allocated Fair Value	$ 20,310
Weighted Average Useful Life (Year)	15 years
Artegraft Inc [Member] \| Intellectual Property [Member]
Allocated Fair Value	$ 16,449
Weighted Average Useful Life (Year)	10 years
Artegraft Inc [Member] \| Noncompete Agreements [Member]
Allocated Fair Value	$ 104
Weighted Average Useful Life (Year)	5 years
Artegraft Inc [Member] \| Trade Names [Member]
Allocated Fair Value	$ 2,193
Weighted Average Useful Life (Year)	10 years
Applied Medical [Member]
Allocated Fair Value		$ 4,844
Applied Medical [Member] \| Customer Relationships [Member]
Allocated Fair Value		$ 3,945
Weighted Average Useful Life (Year)		13 years
Applied Medical [Member] \| Intellectual Property [Member]
Allocated Fair Value		$ 563
Weighted Average Useful Life (Year)		7 years
Applied Medical [Member] \| Noncompete Agreements [Member]
Allocated Fair Value		$ 233
Weighted Average Useful Life (Year)		5 years
Applied Medical [Member] \| Trade Names [Member]
Allocated Fair Value		$ 103
Weighted Average Useful Life (Year)		7 years

Note 8 - Commitments and Contingencies

12 Months Ended

Dec. 31, 2021

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

8. Commitments and Contingencies

Leases

We conduct the majority of our operations in leased facilities, all of which are accounted for as operating leases, as they do not meet the criteria for finance leases. Our principal worldwide executive, distribution, and manufacturing operations are located in five leased facilities with square footage totaling 109,354 in Burlington, Massachusetts. All five Burlington leases expire in December 2030. In addition, our European operations are headquartered at a 16,470 square foot leased facility located in Sulzbach, Germany under a lease which expires in August 2023. This lease contains two five-year renewal options. We also lease a facility in Hereford, England which houses our United Kingdom sales and distribution business. During the quarter ended June 30, 2021 we executed an expansion of the Hereford lease under terms substantially similar to the original lease. In connection with our acquisition of the Artegraft biologic graft business, we assumed a 16,732 square foot lease in North Brunswick, New Jersey, which expires in October 2029. In June 2021 we entered into a six-year lease in Milan, Italy which houses a customer service and warehouse facility. This lease contains a six-year renewal option. We also have smaller long-term leased sales, marketing and other facilities located in Arizona, Canada, Australia, Singapore and China, and short-term leases in Japan, Spain and Illinois. Our lease in Canada contains a five-year renewal option exercisable in February 2023. Our leases in Germany and Italy are subject to periodic rent increases based on increases in the consumer price index as measured on an annual basis, with such increases applicable to the subsequent twelve months of lease payments. None of our noncancelable lease payments include non-lease components such as maintenance contracts; we generally reimburse the landlord for direct operating costs associated with the leased space. We have no subleases, and there are no residual value guarantees associated with, or restrictive covenants imposed by, any of our leases. There were no assets held under capital leases at December 31, 2021.

We also lease automobiles under operating leases in the United States as well as certain of our international subsidiaries. The terms of these leases are generally three years, with older vehicles replaced by newer vehicles from time to time. During the quarter ended June 30, 2021 we entered into a five-year lease for printing equipment.

We account for leases under the provisions of ASU No. 2016-02, Leases (Topic 842), subsequently amended by ASU 2018-11, Leases (Topic 842): Targeted Improvements. Under this guidance, we are required to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term.

Our most significant judgment involved in determining the amounts to initially record as lease liabilities and right-of-use assets upon initial adoption of this standard, and for leases entered into subsequently, was the selection of a discount rate; because we had no debt as of the adoption of this standard, we had no incremental borrowing rate to reference. We therefore derived an incremental borrowing rate using quotes from potential lenders as the primary inputs, augmented by other available information. The resulting rate selected was 5.25%. We determined that it was appropriate to apply this single rate to our portfolio of leases worldwide, as the lease terms and conditions are substantially similar, and because we believe our subsidiaries would be unable to obtain borrowings on their own without a commitment of parent company support. In connection with the assumption of the Artegraft North Brunswick, New Jersey lease, we used LeMaitre’s borrowing rate of 3.5% as of the acquisition date associated with debt incurred to finance the acquisition to value the lease.

Additional information with respect to our leases is as follows:

	Year ended			Year ended
	December 31,			December 31,
	2021			2020
	(in thousands)			(in thousands)

Lease cost
Operating lease cost	$	2,275		$	1,912
Short-term lease cost		458			192
Total lease cost	$	2,733		$	2,104

Other information
Cash paid for amounts included in the measurement of operating lease liabilities	$	2,859		$	2,404

Right-of-use assets obtained in exchange for new operating lease liabilities	$	1,277		$	2,770


Weighted average remaining lease term - operating leases (in years)		7.3			7.8

Weighted average discount rate - operating leases		4.86	%		5.02	%

At December 31, 2021, the minimum noncancelable operating lease rental commitments with initial or remaining terms of more than one year are as follows:

Year ending December 31,
2022	$	2,666
2023		2,300
2024		2,104
2025		2,151
2026		2,153
Thereafter		8,198
Adjustment to net present value as of December 31, 2021		(3,635	)

Minimum noncancelable lease liability	$	15,937

Purchase Commitments

As part of our normal course of business, we have commitments to purchase approximately $6.2 million of inventory through 2022. These purchases are to be used in the normal course of business and do not represent excess commitments or loss contracts.

Note 1 - Significant Accounting Policies and Related Matters - Summary of Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2021
Computers and Equipment [Member] \| Minimum [Member]
Useful life (Year)	3 years
Computers and Equipment [Member] \| Maximum [Member]
Useful life (Year)	5 years
Machinery and Equipment [Member] \| Minimum [Member]
Useful life (Year)	3 years
Machinery and Equipment [Member] \| Maximum [Member]
Useful life (Year)	10 years
Leasehold Improvements [Member] \| Minimum [Member]
Estimated useful life	The shorter of its useful life or lease term
Leasehold Improvements [Member] \| Maximum [Member]
Estimated useful life	The shorter of its useful life or lease term

Note 8 - Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2021

Notes Tables

Lease, Cost [Table Text Block]

	Year ended			Year ended
	December 31,			December 31,
	2021			2020
	(in thousands)			(in thousands)

Lease cost
Operating lease cost	$	2,275		$	1,912
Short-term lease cost		458			192
Total lease cost	$	2,733		$	2,104

Other information
Cash paid for amounts included in the measurement of operating lease liabilities	$	2,859		$	2,404

Right-of-use assets obtained in exchange for new operating lease liabilities	$	1,277		$	2,770


Weighted average remaining lease term - operating leases (in years)		7.3			7.8

Weighted average discount rate - operating leases		4.86	%		5.02	%

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

Year ending December 31,
2022	$	2,666
2023		2,300
2024		2,104
2025		2,151
2026		2,153
Thereafter		8,198
Adjustment to net present value as of December 31, 2021		(3,635	)

Minimum noncancelable lease liability	$	15,937

Note 8 - Commitments and Contingencies - Minimum Rental Commitments (Details) $ in Thousands	Dec. 31, 2021 USD ($)
2022	$ 2,666
2023	2,300
2024	2,104
2025	2,151
2026	2,153
Thereafter	8,198
Adjustment to net present value as of December 31, 2021	(3,635)
Minimum noncancelable lease liability	$ 15,937

Note 15 - Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2021

Notes Tables

Quarterly Financial Information [Table Text Block]

	Three months ended
2021	March 31		June 30		September 30		December 31
	(in thousands, except per share data)
Total net sales	$	35,883	$	40,670	$	38,368	$	39,503
Gross profit		23,799		26,761		24,866		25,956
Income from operations		7,945		11,106		9,073		8,301
Net income		5,929		8,299		6,504		6,175
Earnings per share
Basic	$	0.29	$	0.40	$	0.30	$	0.28
Diluted	$	0.28	$	0.40	$	0.30	$	0.28

	Three months ended
2020	March 31		June 30		September 30		December 31
	(in thousands, except per share data)
Total net sales	$	30,551	$	24,851	$	36,416	$	37,548
Gross profit		20,483		17,029		22,704		24,402
Income from operations		4,353		4,872		10,018		9,545
Net income		3,174		3,500		7,513		7,033
Earnings per share
Basic	$	0.16	$	0.17	$	0.37	$	0.35
Diluted	$	0.16	$	0.17	$	0.37	$	0.34

Note 9 - Income Taxes - Income (Loss) Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
United States	$ 34,153	$ 25,308	$ 17,989
Foreign	134	2,048	3,690
Income before income taxes	$ 34,287	$ 27,356	$ 21,679

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

Note 4 - Property and Equipment

12 Months Ended

Dec. 31, 2021

Notes to Financial Statements

Property, Plant and Equipment Disclosure [Text Block]

4. Property and Equipment

Property and equipment consists of the following:

	As of December 31,
	2021			2020
	(in thousands)
Computers and equipment	$	5,667		$	5,046
Machinery and equipment		18,439			17,266
Building and leasehold improvements		15,884			12,809

Gross property and equipment		39,990			35,121
Less accumulated depreciation		(22,931	)		(20,085	)

Property and equipment, net	$	17,059		$	15,036

During the years ended December 31, 2021, 2020 and 2019 we wrote off fully depreciated assets with gross values of $0.1 million, $0.6 million and $0.5 million, respectively.

Depreciation expense is as follows:

	Year ended December 31,
	2021		2020		2019
			(in thousands)

Depreciation expense	$	3,280	$	3,181	$	2,979

Note 10 - Stockholders' Equity (Details Textual) - USD ($)				12 Months Ended
	Feb. 22, 2022	Aug. 04, 2021	Jul. 16, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Common Stock, Shares Authorized (in shares)				37,000,000	37,000,000
Preferred Stock, Shares Authorized (in shares)				3,000,000	3,000,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				0	0
Stock Issued During Period, Shares, New Issues (in shares)			1,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)			$ 0.01	$ 0.01	$ 0.01
Shares Issued, Price Per Share (in dollars per share)			$ 54.50
Stock Issued During Period, Value, New Issues			$ 51,000,000.0	$ 58,695,000
Proceeds from Issuance of Common Stock				$ 63,241,000	$ 5,971,000	$ 4,856,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)				5,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)				10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)				7,118,003
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)				658,935
Proceeds from Stock Options Exercised				$ 4,500,000	$ 6,000,000.0	$ 4,900,000
Common Stock, Dividends, Per Share, Declared (in dollars per share)				$ 0.44	$ 0.38	$ 0.34
Subsequent Event [Member]
Common Stock, Dividends, Per Share, Declared (in dollars per share)	$ 0.125
Dividends Payable	$ 2,700,000
Dividends Payable, Date to be Paid	Mar. 24, 2022
Dividends Payable, Date of Record	Mar. 08, 2022
Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)				1,150,000
Stock Issued During Period, Value, New Issues				$ 12,000
Treasury Stock, Shares, Acquired (in shares)
Stock Repurchase Program [Member] \| Common Stock [Member]
Treasury Stock, Shares, Acquired (in shares)				0
Stock Repurchase Program [Member] \| Common Stock [Member] \| Subsequent Event [Member]
Stock Repurchase Program, Authorized Amount	$ 20,000,000.0
Share-based Payment Arrangement, Option [Member] \| Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)				4 years
Share-based Payment Arrangement, Option [Member] \| Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)				5 years
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value				$ 2,500,000	$ 1,800,000	$ 2,100,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total				$ 13,100,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)				3 years 3 months 18 days
Underwriters [Member]
Stock Issued During Period, Value, New Issues		$ 150,000
Proceeds from Issuance of Common Stock		$ 7,600,000

Note 10 - Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2021

Notes Tables

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	2021			2020			2019
Dividend yield		0.91	%		1.02	%		0.96	%
Volatility		46.0	%		47.3	%		42.8	%
Risk-free interest rate		1.1	%		0.3	%		1.7	%
Weighted average expected option term (in years)		4.6			4.9			4.7
Weighted average fair value per share of options granted	$	17.64		$	13.24		$	12.51

Share-based Payment Arrangement, Option, Activity [Table Text Block]

				Weighted		Weighted Average		Aggregate
	*Number*			*Average*		*Remaining*		*Intrinsic*
	*of Shares*			*Exercise Price*		*Contractual Term*		*Value*
						(in years)		(in thousands)

Balance outstanding at December 31, 2018		1,462,575		$	16.41		4.54	$	12,214

Granted		195,379		$	35.53
Exercised		(509,693	)	$	9.53			$	11,488
Canceled / Expired		(101,167	)	$	17.90

Balance outstanding at December 31, 2019		1,047,094		$	28.22		4.31	$	13,367

Granted		222,110		$	36.67
Exercised		(331,958	)	$	17.99			$	5,413
Canceled / Expired		(5,406	)	$	27.49

Balance outstanding at December 31, 2020		931,840		$	28.22		4.49	$	11,442

Granted		151,161		$	48.60
Exercised		(217,121	)	$	20.95			$	6,975
Canceled / Expired		(19,126	)	$	23.18
Balance outstanding at December 31, 2021		846,754		$	33.83		4.50	$	13,888

Exercisable at:
December 31, 2019		309,501		$	19.64		3.50	$	5,047
December 31, 2020		274,411		$	23.08		3.50	$	4,781
December 31, 2021		301,692		$	27.40		3.30	$	6,886

Expected to vest at:
December 31, 2019		737,593		$	24.68		4.65
December 31, 2020		657,429		$	30.37		4.93
December 31, 2021		545,062		$	37.38		5.16

Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]

				Weighted
				Average
	*Number*			*Grant Date*
	*of Shares*			*Fair Value*

Balance outstanding at December 31, 2018		217,895		$	21.21

Granted		56,567		$	35.41
Vested		(61,058	)	$	18.46
Canceled		(24,723	)	$	22.19

Balance outstanding at December 31, 2019		188,681		$	26.14

Granted		46,146		$	36.86
Vested		(50,669	)	$	22.76
Canceled		(37,143	)	$	27.88

Balance outstanding at December 31, 2020		147,015		$	30.24

Granted		48,298		$	48.65
Vested		(51,414	)	$	26.32
Canceled		(10,068	)	$	30.70

Balance outstanding at December 31, 2021		133,831		$	38.26

Share-based Payment Arrangement, Performance Shares, Activity [Table Text Block]

			Weighted
			Average
	*Number*		*Grant Date*
	*of Shares*		*Fair Value*

Balance outstanding at December 31, 2020		-	$	-

Granted		31,181	$	48.60
Vested		-	$	-
Canceled		-	$	-

Balance outstanding at December 31, 2021		31,181	$	48.60

Accelerated Share Repurchases [Table Text Block]

	2021		2020		2019

Shares of common stock repurchased for net settlement of equity awards		16,333		16,537		20,524
Average per share repurchase price	$	49.10	$	34.47	$	33.28
Aggregage purchase price (in thousands)	$	802	$	570	$	683

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	2021		2020		2019
	(in thousands)
Stock option awards	$	2,199	$	1,938	$	1,580
Restricted stock units		1,247		1,084		1,062
Performance-based restricted stock units		33		-		-

Total stock-based compensation	$	3,479	$	3,022	$	2,642

	2021		2020		2019
	(in thousands)
Cost of sales	$	407	$	333	$	310
Sales and marketing		527		516		544
General and administrative		2,185		1,883		1,509
Research and development		360		290		279

Total stock-based compensation	$	3,479	$	3,022	$	2,642

Schedule of Dividends Payable [Table Text Block]

Record Date	Payment Date	Per Share Amount		Dividend Payment
				(in thousands)
Fiscal Year 2021
March 9, 2021	March 25, 2021	$	0.110	$	2,262
May 19, 2021	June 3, 2021	$	0.110	$	2,267
August 26, 2021	September 9, 2021	$	0.110	$	2,401
November 19, 2021	December 2, 2021	$	0.110	$	2,405

Fiscal Year 2020
March 3, 2020	March 19, 2020	$	0.095	$	1,917
May 20, 2020	June 4, 2020	$	0.095	$	1,917
August 27, 2020	September 10, 2020	$	0.095	$	1,925
November 19, 2020	December 3, 2020	$	0.095	$	1,936

Note 3 - Inventories and Other Deferred Costs (Details Textual) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross	$ 2.1	$ 2.1

Note 5 - Goodwill and Other Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Goodwill, Purchase Accounting Adjustments		$ 0	$ (1,345)
Impairment of Intangible Assets, Finite-lived		$ 3,400		$ 4,500
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)		2 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)		16 years
Weighted Average [Member]
Finite-Lived Intangible Asset, Useful Life (Year)		11 years
CardioCel and VascuCel Biologic Patches [Member]
Goodwill, Purchase Accounting Adjustments	$ (1,300)		$ 1,300

Note 7 - Accrued Expenses and Other Long-term Liabilities - Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Compensation and related taxes	$ 10,236	$ 8,675
Income and other taxes	551	2,394
Professional fees	129	39
Other	5,416	6,417
Total	$ 16,332	$ 17,525

Note 13 - Fair Value Measurements - Rollforward of the Fair Value as Determined by Level 3 (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Beginning balance	$ 2,240	$ 1,764	$ 72
Additions	0	406	1,989
Payments	0	0	(309)
Change in fair value included in earnings	(748)	70	12
Ending balance	$ 1,492	$ 2,240	$ 1,764

Note 9 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Unrecognized Tax Benefits, Ending Balance	$ 768	$ 820	$ 848	$ 711
Deferred Tax Assets, Valuation Allowance, Total	1,744	1,824
Deferred Tax Assets, Operating Loss Carryforwards, Total	1,153	1,348
Deferred Tax Assets, Capital Loss Carryforwards	492	521
Foreign Tax Authority [Member] \| AUSTRALIA
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	(100)	$ 400
Deferred Tax Assets, Operating Loss Carryforwards, Total	1,400
Deferred Tax Assets, Capital Loss Carryforwards	1,600
Foreign Tax Authority [Member] \| FRANCE
Deferred Tax Assets, Operating Loss Carryforwards, Total	2,100
Foreign Tax Authority [Member] \| SPAIN
Deferred Tax Assets, Operating Loss Carryforwards, Total	800
Foreign Tax Authority [Member] \| NORWAY
Deferred Tax Assets, Operating Loss Carryforwards, Total	100
State and Local Jurisdiction [Member]
Tax Credit Carryforward, Amount	$ 1,600

Note 7 - Accrued Expenses and Other Long-term Liabilities - Other Long-term Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Acquisition-related liabilities	$ 1,761	$ 3,700
Income taxes	799	813
Other	141	130
Total	$ 2,701	$ 4,643

Note 1 - Significant Accounting Policies and Related Matters

12 Months Ended

Dec. 31, 2021

Notes to Financial Statements

Significant Accounting Policies [Text Block]

1. Significant Accounting Policies and Related Matters

Description of Business

Unless the context requires otherwise, references to LeMaitre, LeMaitre Vascular, we, our, and us refer to LeMaitre Vascular, Inc. and our subsidiaries. We develop, manufacture, and market medical devices and implants used primarily in the field of vascular surgery. We also derive revenues from the processing and cryopreservation of human tissues for implantation in patients. We operate in a single segment in which our principal product lines include the following: anastomotic clips, angioscopes, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy catheters, occlusion catheters, radiopaque marking tape, synthetic vascular grafts and valvulotomes. Our offices and production facilities are located in Burlington, Massachusetts; Fox River Grove, Illinois; North Brunswick, New Jersey; Chandler, Arizona; Vaughan, Canada; Sulzbach, Germany; Milan, Italy; Madrid, Spain; Saint-Etienne, France; Hereford, England; Kensington, Australia; Tokyo, Japan; Shanghai, China; and Singapore.

Consolidation and Basis of Presentation

Our consolidated financial statements include the accounts of LeMaitre Vascular and the accounts of our wholly-owned subsidiaries, LeMaitre Vascular GmbH, LeMaitre Vascular GK, Vascutech Acquisition LLC, LeMaitre Acquisition LLC, LeMaitre Vascular SAS, LeMaitre Vascular S.r.l., LeMaitre Vascular Spain SL, LeMaitre Vascular Switzerland GmbH, LeMaitre Vascular ULC, LeMaitre Vascular AS, LeMaitre Vascular Pty Ltd, Bio Nova International Pty Ltd, LeMaitre Vascular, Ltd., LeMaitre Medical Technology (Shanghai) Co. Ltd, LeMaitre Cardial SAS and LeMaitre Pte Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation.

Foreign Currency Translation

Balance sheet accounts of foreign subsidiaries are translated into U.S. dollars at year-end exchange rates. Operating accounts are translated at average exchange rates for each year. Net translation gains or losses are adjusted directly to a separate component of other comprehensive income (loss) within stockholders’ equity. Foreign exchange transaction gains (losses), substantially all of which relate to intercompany activity between us and our foreign subsidiaries, are included in other income (expense) in the accompanying consolidated statements of operations.

Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in in our consolidated financial statements and accompanying notes. Due to the COVID-19 pandemic, there is heightened volatility and uncertainty in customer demand and the worldwide economy in general. However, the magnitude and duration of the impact on our revenues and operations from COVID-19 is uncertain and cannot currently be reasonably estimated at this time. The Company is not aware of any specific event or circumstance that would require an update to its accounting estimates or adjustments to the carrying value of its assets and liabilities as of February 28, 2022, the issuance date of this Annual Report on Form 10-K. Actual results could differ from those estimates, particularly if the Company experiences material impacts to the carrying value of its assets and liabilities from COVID-19.

Revenue Recognition

Our revenue is derived primarily from the sale of disposable or implantable devices used during vascular surgery. We sell primarily directly to hospitals and to a lesser extent to distributors, as described below, and, during the periods presented in our consolidated financial statements, entered into consigned inventory arrangements with either hospitals or distributors on a limited basis. With the acquisition of the RestoreFlow allograft business, we also derive revenues from the processing and cryopreservation of human tissues for implantation in patients. These revenues are recognized when services have been provided and the tissue has been shipped to the customer, provided all other revenue recognition criteria discussed in the succeeding paragraph have been met.

We record revenue under the provisions of ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The core principle of Topic 606 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard explains that to achieve the core principle, an entity should take the following actions:

Step 1: Identify the contract with a customer

Step 2: Identify the performance obligations in the contract

Step 3: Determine the transaction price

Step 4: Allocate the transaction price

Step 5: Recognize revenue when or as the entity satisfies a performance obligation

Revenue is recognized when or as a company satisfies a performance obligation by transferring a promised good or service to a customer (which is when the customer obtains control of that good or service). In instances in which shipping and handling activities are performed after a customer takes control of the goods (such as when title passes upon shipment from our dock), we have made the policy election allowed under Topic 606 to account for these activities as fulfillment costs and not as performance obligations.

We generally reference customer purchase orders to determine the existence of a contract. Orders that are not accompanied by a purchase order are confirmed with the customer either in writing or verbally. The purchase orders or similar correspondence, once accepted, identify the performance obligations as well as the transaction price, and otherwise outline the rights and obligations of each party. We allocate the transaction price of each contract among the performance obligations in accordance with the pricing of each item specified on the purchase order, which is in turn based on standalone selling prices per our published price lists. In cases where we discount products or provide certain items free of charge, we allocate the discount proportionately to all performance obligations, unless it can be demonstrated that the discount should be allocated entirely to one or more, but not all, of the performance obligations.

We record revenue, net of allowances for returns and discounts, fees paid to group purchasing organizations, and any sales and value added taxes required to be invoiced, which we have elected to exclude from the measurement of the transaction price as allowed by the standard, at the time of shipment (taking into consideration contractual shipping terms), or in the case of consigned inventory, when it is consumed. Shipment is the point at which control of the product and title passes to our customers, and at which LeMaitre has a present right to receive payment for the goods.

Below is a disaggregation of our revenue by major geographic area, which is among the primary categorizations used by management in evaluating financial performance, for the periods indicated (in thousands):

Year ended December 31,

2021

2020

Americas
$ 102,265 $ 81,470

Europe, Middle East and Africa
42,132 39,193

Asia Pacific
10,027 8,703

Total $ 154,424 $ 129,366

We do not carry any contract assets or contract liabilities, as there are generally no unbilled amounts due from customers under contracts for which we have partially satisfied performance obligations, or amounts received from customers for which we have not satisfied performance obligations. We satisfy our performance obligations under revenue contracts within a very short time period from receipt of the orders, and payments from customers are typically received within 30 to 60 days of fulfillment of the orders, except in certain geographies such as Spain and Italy where the payment cycle is customarily longer. Accordingly, there is no significant financing component to our revenue contracts. Additionally, we have elected as a policy that incremental costs (such as commissions) incurred to obtain contracts are expensed as incurred, due to the short-term nature of the contracts.

Customers returning products may be entitled to full or partial credit based on the condition and timing of the return. To be accepted, a returned product must be unopened (if sterile), unadulterated, and undamaged, must have at least 18 months remaining prior to its expiration date, or twelve months for our hospital customers in Europe, and generally be returned within 30 days of shipment. These return policies apply to sales to both hospitals and distributors. The amount of products returned to us, either for exchange or credit, has not been material. Nevertheless, we provide for an allowance for future sales returns based on historical return experience, which requires judgment. Our cost of replacing defective products has not been material and is accounted for at the time of replacement.

Research and Development Expense

Research and development costs, principally salaries, laboratory testing, and supplies, are expensed as incurred and also include royalty payments associated with licensed and acquired intellectual property.

Shipping and Handling Costs

Shipping and handling fees paid by customers are recorded within net sales, with the related expense recorded in cost of sales.

Advertising Costs

Advertising costs are expensed as incurred and are included as a component of sales and marketing expense in the accompanying consolidated statements of operations. Advertising costs are as follows:

Year ended December 31,

2021

2020

2019

(in thousands)

Advertising expense
$ 236 $ 216 $ 286

Cash and Cash Equivalents

We consider all highly liquid instruments purchased with maturity dates of 90 days or less to be cash equivalents. Cash and cash equivalents are primarily invested in money market funds. These amounts are stated at cost, which approximates fair value.

Short-term Marketable Securities

Our short-term marketable securities are available-for-sale securities carried at fair value, with unrealized gains and losses recorded in other comprehensive income. They include a managed income mutual fund investing mainly in short-term investment-grade, U.S. dollar denominated fixed and floating rate debt, and a short-duration bond fund.

Concentrations of Credit Risk

Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Cash equivalents represent highly liquid investments with maturities of 90 days or less at the date of purchase. Credit risk related to cash and cash equivalents are limited based on the creditworthiness of the financial institutions at which these funds are held. We maintain cash balances in several banks. Accounts located in the United States are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. Certain of our account balances exceed the FDIC limit. Cash balances held outside the United States totaled approximately $9.4 million as of December 31, 2021.

Our accounts receivable are with customers based in the United States and internationally. Accounts receivable generally are due within 30 to 90 days of invoice and are stated at amounts due from customers, net of an allowance for doubtful accounts and sales returns, other than in certain European markets where longer payment terms are customary and may range from 90 to 240 days. We perform ongoing credit evaluations of the financial condition of our customers and adjust credit limits based upon payment history and the current creditworthiness of the customers, as determined by a review of their current credit information. We continuously monitor aging reports, collections, and payments from customers, and maintain a provision for estimated credit losses based upon historical experience and any specific customer collection issues we identify.

We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our European sales to government-owned or supported customers such as hospitals, distributors and agents, particularly in Italy and Spain, may be subject to significant payment delays due to government austerity measures impacting funding and payment practices. As of December 31, 2021 our receivables in Italy and Spain totaled $1.0 million and $0.7 million, respectively. Receivables balances with certain government-owned hospitals and government supported customers in these countries can accumulate over a period of time and then subsequently be settled as large lump sum payments. While we believe our allowance for doubtful accounts in these countries is adequate as of December 31, 2021, if significant changes were to occur in the payment practices of these European governments or if government funding becomes unavailable, we may not be able to collect on receivables due to us from these customers and our write offs of uncollectible amounts may increase.

We write off accounts receivable when they become uncollectible. Such credit losses have historically been within our expectations and allowances. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable. We review our allowance for doubtful accounts on a monthly basis and all past due balances are reviewed individually for collectability. The provision for the allowance for doubtful accounts is recorded in general and administrative expenses. The following is a summary of our allowance for doubtful accounts and sales returns:

Balance at

Additions

Deductions

Balance at

Beginning

(recoveries) charged

from

End of

of Period

to Income

Reserves

Period

(in thousands)

Allowance for doubtful accounts and sales returns:

Year ended December 31, 2021
$ 623 $ 263 $ 207 $ 679

Year ended December 31, 2020
522 293 192 623

Year ended December 31, 2019
399 388 265 522

Fair Value of Financial Instruments

Our financial instruments include cash and cash equivalents, short-term marketable securities, accounts receivable and trade payables. The fair value of these instruments approximates their carrying value based upon their short-term nature or variable rates of interest. Unrealized gains and losses on our short-term marketable securities are recorded in other comprehensive income and were not material to our consolidated financial statements for the year ended December 31, 2021.

Inventory and Other Deferred Costs

Inventory and Other Deferred Costs consists of finished products, work-in-process, raw materials and costs deferred in connection with human tissue cryopreservation services of our RestoreFlow allograft business. We value inventory and other deferred costs at the lower of cost or market value. Cost includes materials, labor and manufacturing overhead and is determined using the first-in, first-out (FIFO) method. On a quarterly basis, we review inventory quantities on hand and analyze the provision for excess and obsolete inventory based primarily on product expiration dating and our estimated sales forecast, which is based on sales history and anticipated future demand. Our estimates of future product demand may not be accurate, and we may understate or overstate the provision required for excess and obsolete inventory. Accordingly, any significant unanticipated changes in demand could have a significant impact on the value of our inventory and results of operations.

Property and Equipment

Property and equipment are recorded at cost. Depreciation is provided over the estimated useful lives of the related assets using straight-line method as follows:

Description

Useful Life (in years)

Computers and equipment
3
–
5

Machinery and equipment
3
–
10

Leasehold improvements

The shorter of its useful life or lease term

Expenditures for maintenance and repairs are charged to operations when incurred, while additions and betterments are capitalized. When assets are retired or disposed, the asset’s original cost and related accumulated depreciation are eliminated from the accounts and any gain or loss is reflected in the statement of operations.

Valuation of Business Combinations

We assign the value of the consideration transferred to acquire a business to the tangible assets and identifiable intangible assets acquired and liabilities assumed on the basis of their fair values at the date of acquisition. We assess the fair value of assets, including intangible assets, using a variety of methods and are usually performed by an independent appraiser who measures fair value from the perspective of a market participant.

Acquisitions have been accounted for using the acquisition method, and the acquired companies’ results have been included in the accompanying consolidated financial statements from their respective dates of acquisition. Acquisition transaction costs have been recorded in general and administrative expenses, and are expensed as incurred. Allocation of the purchase price for acquisitions is based on estimates of the fair value of the net assets acquired and, for acquisitions completed within the past year, is subject to adjustment upon finalization of the purchase price allocation.

Our acquisitions have historically been made at prices above the fair value of the acquired assets, resulting in goodwill, due to expectations of synergies of combining the businesses. These synergies include use of our existing commercial infrastructure to expand sales of the acquired businesses’ products, use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of our products, and the elimination of redundant facilities, functions and staffing.

Contingent Consideration

Contingent consideration for acquisitions is recognized at the date of acquisition, based on the fair value at that date, and then re-measured periodically through adjustments to net income.

Impairment of Long-lived Assets

We review our long-lived assets (primarily property and equipment and intangible assets) subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall, or an adverse action or assessment by a regulator. If an impairment indicator exists, we test the intangible asset for recoverability. We record impairment losses on long-lived assets used in operations when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. Impairment is measured based on the fair market value of the affected asset using discounted cash flows.

Goodwill

Goodwill represents the amount of consideration paid in connection with business acquisitions in excess of the fair value of assets acquired and liabilities assumed. Goodwill is evaluated for impairment annually, or more frequently if indicators of impairment are present or changes in circumstances suggest that an impairment may exist. We evaluate the December 31 balance of the carrying value of goodwill based on a single reporting unit annually. We perform an assessment of qualitative factors to determine if it is “more likely than not” that the fair value of our reporting unit is less than its carrying value as a basis for determining whether it is necessary to perform the quantitative goodwill impairment test. The “more likely than not” threshold is defined as having a likelihood of more than 50 percent. The quantitative goodwill impairment test compares the fair value of a reporting unit with its carrying amount, including goodwill. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired. If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit. We have determined that no goodwill impairment charges were required for the years ended December 31, 2021, 2020 or 2019.

Other Intangible Assets

Other intangible assets consist primarily of patents, trademarks, technology licenses, and customer relationships acquired in connection with business acquisitions and asset acquisitions and are amortized over their estimated useful lives, ranging from 2 to 16 years.

Stock-based Compensation

We recognize, as expense, the estimated fair value of stock options to employees determined using the Black-Scholes option pricing model. Share-based compensation charges are recorded across the consolidated statement of operations based upon the grantee’s primary function. We have elected to recognize the compensation cost of all share-based awards on a straight-line basis over the vesting period of the award. In periods that we grant stock options, fair value assumptions are based on volatility, interest, dividend yield, and expected term over which the stock options will be outstanding. The computation of expected volatility is based on the historical volatility of the company’s stock. The interest rate for periods within the contractual life of the award is based on the U.S. Treasury risk-free interest rate in effect at the time of grant. Historical data on exercise patterns is the basis for estimating the expected life of an option. The expected annual dividend rate was calculated by dividing our annual dividend, based on the most recent quarterly dividend rate, by the closing stock price on the grant date.

We also issue restricted stock units (RSUs) and performance-based restricted stock units (PSUs) as additional forms of equity compensation to our employees, officers, and directors, pursuant to our stockholder-approved 2006 Plan. RSUs entitle the grantee to an issuance of stock at no cost and generally vest over a period of time determined by our Board of Directors at the time of grant. PSUs awarded in 2021 will vest based on achievement of operating income for 2021 against budgeted operating income as approved by our Board of Directors. The fair market value of the award is determined based on the number of RSUs and PSUs granted and the market value of our common stock on the grant date and is amortized to expense over the period of vesting. Unvested RSUs and PSUs are forfeited and canceled as of the date that employment or service to the company terminates. RSUs and PSUs are settled in shares of our common stock upon vesting. We typically repurchase common stock upon our employees’ vesting in RSUs and PSUs in order to cover any minimum tax withholding liability as a result of the awards having vested.

Commitments and Contingencies

In the normal course of business, we are subject to proceedings, lawsuits, and other claims and assessments for matters related to, among other things, patent infringement, business acquisitions, employment, commercial matters and product recalls. We assess the likelihood of any adverse judgments or outcomes to these matters as well as potential ranges of probable losses. A determination of the amount of reserves required, if any, for these contingencies is made after careful analysis of each individual issue. The required reserves may change in the future due to new developments or changes in approach, such as a change in settlement strategy in dealing with each matter. We record charges for anticipated losses in connection with litigation and claims against us when we conclude a loss is probable and we can reasonably estimate the loss. During the years ended December 31, 2021, 2020 and 2019, we were not subject to any material litigation or claims and assessments.

Sales of medical devices outside the U.S. are subject to international regulatory requirements that vary from country to country. These requirements and the amount of time required for approval may differ from our experiences with the U.S. FDA. In the European Union we are required to obtain CE marks for our products, which denote conformity to essential requirements for manufacturers of higher-risk devices. Failure to obtain, retain or maintain these CE marks would impact our ability to sell our products in certain European countries and could cause our business to suffer. There can be no assurance that we will be able to obtain or maintain the required regulatory approvals in these countries.

Income Taxes

We account for income taxes under the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred taxes are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The provision for income taxes includes taxes currently payable and deferred taxes resulting from the tax effects of temporary differences between the financial statement and tax bases of assets and liabilities. We maintain valuation allowances where it is more likely than not that all or a portion of a deferred tax asset will not be realized. Changes in the valuation allowances are included in our tax provision in the period of change. In determining whether a valuation allowance is warranted, we evaluate factors such as prior earnings history, expected future earnings, carry-back and carry-forward periods and tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset.

We recognize, measure, present and disclose in our financial statements, uncertain tax positions that we have taken or expect to take on a tax return. We recognize in our financial statements the impact of tax positions that meet a “more likely than not” threshold, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement.

Our policy is to classify interest and penalties related to unrecognized tax benefits as income tax expense.

Comprehensive Income

Comprehensive income is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other than reported net income, comprehensive income includes foreign currency translation adjustments and unrealized gains and losses on our marketable securities, which are disclosed in the accompanying consolidated statements of comprehensive income. There were no reclassifications out of comprehensive income for the years ended December 31, 2021, 2020 or 2019.

Accumulated other comprehensive loss consisted primarily of foreign currency translation adjustment losses of $3.1 million and $1.6 million as of December 31, 2021 and 2020, respectively.

Restructuring

We record restructuring charges incurred in connection with consolidation or relocation of operations, exited business lines, reductions in force, or distributor terminations. These restructuring charges, which reflect our commitment to a termination or exit plan that will begin within twelve months, are based on estimates of the expected costs associated with site closure, legal matters, contract terminations, severance payments, or other costs directly related to the restructuring. If the actual cost incurred exceeds the estimated cost, an additional charge to earnings will result. If the actual cost is less than the estimated cost, a credit to earnings will be recognized.

Earnings per Share

We compute basic earnings per share by dividing net income available for common stockholders by the weighted average number of shares outstanding during the year. Except where the result would be anti-dilutive to net income per share, diluted earnings per share has been computed using the treasury stock method and reflects the potential vesting of restricted common stock and the potential exercise of stock options, as well as their related income tax effects.

The computation of basic and diluted net income per share is as follows:

Year ended December 31,

2021

2020

2019

(in thousands, except per share data)

Basic:

Net income available for common stockholders
$ 26,907 $ 21,220 $ 17,934

Weighted average shares outstanding
21,157 20,246 19,813

Basic earnings per share $ 1.27 $ 1.05 $ 0.91

Net income available for common stockholders
$ 26,907 $ 21,220 $ 17,934

Weighted-average shares outstanding
21,157 20,246 19,813

Common stock equivalents, if dilutive
318 233 513

Shares used in computing diluted earnings per common share
21,475 20,479 20,326

Diluted earnings per share $ 1.25 $ 1.04 $ 0.88

Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive
10 483 468

Recent Accounting Pronouncements

In December 2019, the FASB issued ASU 2019-12 Income Taxes (Topic 740), which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 as well as clarifying and amending other areas of existing GAAP under Topic 740. The new standard was effective for us beginning January 1, 2021, and adoption of this standard did not have a material impact on our financial statements.

Note 9 - Income Taxes - Reconciliation of the Federal Statutory Rate to Effective Tax Rate (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Federal statutory rate	21.00%	21.00%	21.00%
State tax, net of federal benefit	2.70%	2.20%	1.90%
Effect of foreign taxes	3.70%	1.10%	2.10%
Federal tax on foreign income	0.20%	0.40%	0.80%
Valuation allowance	(0.10%)	1.40%	0.60%
Foreign deferred tax liability offset	(0.10%)	(0.20%)	(0.40%)
Research & development tax credits	(0.40%)	(0.60%)	(1.20%)
Stock options	(3.10%)	(2.30%)	(8.80%)
Uncertain tax positions	0.20%	0.30%	1.00%
Other permanent differences	(2.40%)	(0.60%)	0.50%
Other	(0.20%)	(0.30%)	(0.20%)
Effective tax rate	21.50%	22.40%	17.30%

Note 13 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2021	Oct. 11, 2019
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability		$ (674)	$ 182	$ 171
Artegraft Inc [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		17,500
Business Combination, Contingent Consideration, Liability, Total		400
CardioCel and VascuCel Biologic Patches [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High				7,800
Business Combination, Contingent Consideration, Liability, Total					$ 2,000	$ 7,500
CardioCel and VascuCel Biologic Patches [Member] \| Audited Carve-Out Financial Statements of the Acquired Business [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High				300
CardioCel and VascuCel Biologic Patches [Member] \| Third Holdback [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High				2,000
Business Combination, Contingent Consideration, Liability, Total						2,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	$ (500)
CardioCel and VascuCel Biologic Patches [Member] \| Extension of Product Shelf Life from 36 Months to 60 Months in the First Anniversary of Closing Date [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High				500
Business Combination, Contingent Consideration, Liability, Total						500
CardioCel and VascuCel Biologic Patches [Member] \| Achievement of Specified Levels of Revenues [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High				$ 5,000
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Recurring [Member]
Assets, Fair Value Disclosure		$ 0
Fair Value, Inputs, Level 3 [Member] \| CardioCel and VascuCel Biologic Patches [Member]
Business Combination, Contingent Consideration, Liability, Total						$ 2,300

Note 9 - Income Taxes

12 Months Ended

Dec. 31, 2021

Notes to Financial Statements

Income Tax Disclosure [Text Block]

9. Income Taxes

Income (loss) before income taxes is as follows:

	Year ended December 31,
	2021		2020		2019
	(in thousands)

United States	$	34,153	$	25,308	$	17,989
Foreign		134		2,048		3,690

Total	$	34,287	$	27,356	$	21,679

Certain of our foreign subsidiaries are included in the U.S. tax return as branches but are included as foreign for purposes of the table above.

The provision (benefit) for income taxes is as follows:

	Year ended December 31,
	2021			2020			2019
				(in thousands)
Current:
Federal	$	5,024		$	4,594		$	1,501
State		990			806			304
Foreign		1,287			1,064			1,116

		7,301			6,464			2,921
Deferred:
Federal		63			(397	)		538
State		(9	)		(48	)		144
Foreign		25			117			142

		79			(328	)		824

Provision for income taxes	$	7,380		$	6,136		$	3,745

We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of December 31, 2021, the gross amount of unrecognized tax benefits exclusive of interest and penalties was $0.8 million, which may increase within the twelve months ending December 31, 2022. We remain subject to examination until the statute of limitations expires for each remaining respective tax jurisdiction. The statute of limitations will be open with respect to these tax positions through 2030. A reconciliation of the beginning and ending amount of our unrecognized tax benefits is as follows:

	2021			2020			2019
	(in thousands)
Unrecognized tax benefits at the beginning of year	$	820		$	848		$	711
Additions/adjustments for tax positions of current year		-			-			74
Additions/adjustments for tax positions of prior years		(52	)		37			63
Reductions for settlements with taxing authorities.		-			(65	)		-
Reductions for lapses of the applicable statutes of limitations		-			-			-
Unrecognized tax benefits at the end of the year	$	768		$	820		$	848

Deferred taxes are attributable to the following temporary differences:

	As of December 31,
	2021			2020
	(in thousands)
Deferred tax assets:
Inventory	$	2,231		$	1,629
Net operating loss carryforwards		1,153			1,348
Tax credit carryforwards		1,033			1,019
Capital loss carryforwards		492			521
Reserves and accruals		712			994
Operating lease liabilities		3,562			3,664
Intangible assets		4,426			4,386
Stock options		440			359
Other		140			105

Total deferred tax assets		14,189			14,025

Deferred tax liabilities:
Property and equipment		(1,713	)		(1,831	)
Goodwill		(4,825	)		(4,055	)
Operating lease right-of-use assets		(3,355	)		(3,503	)
Foreign branch deferred offset		(843	)		(954	)
Other		(213	)		(299	)

Total deferred tax liabilities		(10,949	)		(10,642	)

Net deferred tax assets before valuation allowance		3,240			3,383

Valuation allowance		(1,744	)		(1,824	)

Net deferred tax liabiltity	$	1,496		$	1,559

Deferred tax classification
Long-term deferred tax asset	$	1,566		$	1,686
Long-term deferred tax liability		(70	)		(127	)

Net long-term deferred tax asset	$	1,496		$	1,559

In 2020, we increased our valuation allowance by $0.4 million mainly attributable to Australian net operating loss carry forwards and Massachusetts credit carryforwards. In 2021, we decreased our valuation allowance by $0.1 million mainly attributable to Australian net operating loss carry forwards and Massachusetts credit carryforwards.

As of December 31, 2021, we have provided a valuation allowance of $1.7 million for deferred tax assets primarily related to Australian net operating loss and capital loss carry forwards and Massachusetts tax credit carry forwards that are not expected to be realized. The valuation allowance against our deferred tax assets may require adjustment in the future based on changes in the mix of temporary differences, changes in tax laws, and operating performance.

Realization of our deferred tax assets is dependent on our generating sufficient taxable income in future periods. Although we believe it is more likely than not that future taxable income will be sufficient to allow us to recover substantially all of the value of our deferred tax assets remaining after we apply the valuation allowances, realization is not assured and future events could cause us to change our judgment. In the event that actual results differ from our estimates, or we adjust these estimates in the future periods, further adjustments to our valuation allowance may be recorded, which could materially impact our financial position and net income (loss) in the period of the adjustment.

As of December 31, 2021, we have net operating loss carryforwards in Australia of $1.4 million that do not expire, in France of $2.1 million that do not expire, in Spain of $0.8 million that do not expire, and in Norway of $0.1 million that do not expire. We have a capital loss carryforward in Australia of $1.6 million that does not expire. We also have state tax credit carryforwards of approximately $1.6 million that are available to reduce future tax liabilities, which begin to expire in 2030, or can be carried forward indefinitely.

In December 2018, we reevaluated our international operations and as a result, are no longer indefinitely reinvested with respect to undistributed earnings from our German and Australian subsidiaries. There was no material deferred tax expense recorded for foreign and state tax costs associated with the future remittance of these undistributed earnings. We remain permanently reinvested with respect to undistributed earnings from our other foreign subsidiaries. It is not practicable to estimate the amount of deferred tax liability, if any, with respect to these permanently reinvested undistributed earnings.

A reconciliation of the U.S. federal statutory rate to our effective tax rate is as follows:

	2021			2020			2019

Federal statutory rate		21.0	%		21.0	%		21.0	%
State tax, net of federal benefit		2.7	%		2.2	%		1.9	%
Effect of foreign taxes		3.7	%		1.1	%		2.1	%
Federal tax on foreign income		0.2	%		0.4	%		0.8	%
Valuation allowance		(0.1	%)		1.4	%		0.6	%
Foreign deferred tax liability offset		(0.1	%)		(0.2	%)		(0.4	%)
Research & development tax credits		(0.4	%)		(0.6	%)		(1.2	%)
Stock options		(3.1	%)		(2.3	%)		(8.8	%)
Uncertain tax positions		0.2	%		0.3	%		1.0	%
Other permanent differences		(2.4	%)		(0.6	%)		0.5	%
Other		(0.2	%)		(0.3	%)		(0.2	%)

Effective tax rate		21.5	%		22.4	%		17.3	%

We are not currently under income tax audit in any tax jurisdictions.

As of December 31, 2021, a summary of the tax years that remain subject to examination in our most significant tax jurisdictions are:

United States	2018 and forward
Foreign	2014 and forward

Supplemental disclosures of cash flow information are as follows:

	Year ended December 31,
	2021		2020		2019
	(in thousands)
Cash paid for income taxes, net	$	10,147	$	4,470	$	4,817

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details